https://trial.medpath.com/news/neurocrine-biosciences-initiates-phase-1-trial-for-novel-crf2-agonist-nbip-2118-in-obesity-treatment 2026-05-04T13:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-lake-pharma-becomes-first-chinese-company-to-secure-fda-approval-for-insulin-glargine-in-us-market 2026-05-04T13:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/grin-therapeutics-expands-phase-3-beeline-trial-to-europe-for-rare-neurodevelopmental-disorder-treatment 2026-05-04T13:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/rose-bengal-sodium-shows-light-independent-activity-against-mrsa-and-biofilms-in-new-u-s-patent-expanding-visirose-s-ophthalmic-pipeline 2026-05-04T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/kwangdong-pharmaceutical-secures-first-generic-exclusivity-for-tagrisso-joining-chong-kun-dang-in-race-for-korea-s-krw-110-billion-nsclc-market 2026-05-04T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-endoxifen-shows-promise-for-breast-cancer-prevention-with-reduced-side-effects 2026-05-04T09:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-and-almirall-advance-first-dermatology-drug-candidate-in-record-time-using-ai-driven-platform 2026-05-04T09:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-acquires-candid-therapeutics-for-2-2-billion-advancing-t-cell-engager-platform-for-autoimmune-diseases 2026-05-04T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/b-braun-launches-first-fda-approved-room-temperature-stable-rocuronium-bromide-prefilled-syringe 2026-05-04T08:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mrna-lnp-cancer-therapy-harnesses-pre-existing-measles-immunity-to-enhance-tumor-killing-cd8-t-cells 2026-05-04T05:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/futurechem-receives-korean-approval-for-prostaview-prostate-cancer-diagnostic-marking-second-global-psma-pet-agent 2026-05-04T05:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/d-d-pharmatech-raises-165m-as-mash-drug-dd01-approaches-key-phase-2-readout 2026-05-04T05:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/novelty-nobility-expands-partnership-with-agc-biologics-for-first-in-class-bispecific-antibody-nn4101 2026-05-04T05:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-assisted-therapy-achieves-75-response-rate-in-treatment-resistant-ibs-patients 2026-05-04T05:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/xtalpi-enabled-prmt5-inhibitor-pep08-reaches-phase-i-enrollment-milestone-in-solid-tumor-trial 2026-05-04T05:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-drive-pharma-r-d-returns-to-7-as-obesity-overtakes-oncology-in-pipeline-value 2026-05-04T05:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/prometheus-laboratories-advances-next-generation-blood-test-for-mash-patient-identification 2026-05-03T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/everads-therapy-reports-positive-first-in-human-data-for-novel-suprachoroidal-drug-delivery-system-in-diabetic-macular-edema 2026-05-03T17:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-ucb-s-rystiggo-for-myasthenia-gravis-treatment-on-nhs-in-england 2026-05-03T13:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/certara-and-nvidia-partner-to-bring-ai-powered-autonomous-agents-to-drug-development 2026-05-03T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/minimal-residual-disease-pipeline-set-for-strategic-expansion-by-2026-with-emerging-immunotherapies-and-precision-diagnostics 2026-05-02T21:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-show-promise-in-reducing-heart-transplant-rejection-risk-in-diabetic-patients 2026-05-02T21:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/liquid-biopsy-blood-tests-predict-breast-cancer-immunotherapy-response-in-vanderbilt-study 2026-05-02T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-blinatumomab-effectiveness-as-bridge-to-transplant-in-b-cell-precursor-all 2026-05-02T21:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/inspiremd-receives-fda-approval-for-cguardians-iii-pivotal-study-of-switchguard-neuro-protection-system 2026-05-02T21:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/novel-conditioning-regimen-achieves-100-2-year-survival-in-sickle-cell-transplant-study 2026-05-02T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/billiontoone-launches-unity-confirm-non-invasive-fetal-cell-test-bridges-gap-between-screening-and-invasive-diagnostics 2026-05-02T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/bytedance-s-anew-labs-presents-first-ai-designed-therapy-targeting-previously-undruggable-il-17-protein 2026-05-02T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/convergent-evolution-in-aplastic-anemia-independent-hla-loss-clones-drive-remission-without-increasing-leukemia-risk 2026-05-02T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-ai-model-detects-pancreatic-cancer-nearly-3-years-before-clinical-diagnosis 2026-05-02T09:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-lower-hyperglycemia-management-burden-with-capivasertib-versus-alpelisib-in-metastatic-breast-cancer 2026-05-02T09:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/sonire-therapeutics-launches-first-u-s-clinical-trial-of-ultrasound-guided-hifu-for-pancreatic-cancer 2026-05-02T01:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/antibiotic-minocycline-shows-promise-as-novel-treatment-for-panic-disorder-in-clinical-trial 2026-05-02T01:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/sparc-sells-rare-pediatric-disease-priority-review-voucher-for-195-million-following-sezaby-approval 2026-05-02T01:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/iterative-health-secures-77m-series-c-to-expand-ai-powered-clinical-trial-network 2026-05-02T01:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-cancels-500m-share-sale-amid-ivonescimab-data-debate 2026-05-01T22:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-protac-drug-veppanu-for-esr1-mutated-breast-cancer 2026-05-01T22:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/weill-cornell-researchers-reverse-engineer-ketamine-s-antidepressant-mechanism-paving-way-for-safer-alternatives 2026-05-01T22:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/lakewood-amedex-reports-low-resistance-development-for-novel-antimicrobial-nu-3-in-diabetic-foot-ulcer-treatment 2026-05-01T17:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-mri-study-validates-immune-response-mechanism-of-mvp-s-combination-therapy-in-ovarian-cancer 2026-05-01T17:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/us-maintains-pressure-on-india-s-pharmaceutical-patent-system-through-priority-watch-list-designation 2026-05-01T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/quadruple-immunotherapy-shows-durable-complete-response-in-mss-metastatic-colorectal-cancer-but-lacks-reproducibility 2026-05-01T17:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/corcept-s-dazucorilant-shows-87-reduction-in-death-risk-for-als-patients-despite-missing-primary-endpoint 2026-05-01T13:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-compass-outperforms-existing-methods-in-predicting-response-to-cancer-immunotherapy 2026-05-01T13:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-presents-positive-phase-3-data-for-low-dose-estrogen-contraceptive-patch-at-acog-2026 2026-05-01T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/immuno-pet-imaging-reveals-body-wide-immune-response-to-oncolytic-virotherapy-in-head-and-neck-cancer 2026-05-01T09:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/oberland-biotech-secures-chf-2-5-million-seed-funding-to-advance-biotechnology-and-nutritional-food-innovation 2026-05-01T09:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-acquires-imidomics-patient-insight-business-to-advance-precision-medicine-in-immune-mediated-inflammatory-diseases 2026-05-01T09:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/factor-bioscience-advances-il-12-engineered-imacrophage-therapy-for-solid-tumors-with-promising-ovarian-cancer-data 2026-05-01T05:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/usc-team-maps-spinal-cord-address-for-bladder-control-restoring-voiding-in-91-7-of-trials 2026-05-01T05:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-reports-positive-phase-1b-results-for-pipe-791-in-chronic-pain-treatment 2026-05-01T05:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/cflip-identified-as-novel-therapeutic-vulnerability-in-aggressive-abc-dlbcl-overcoming-treatment-resistance 2026-05-01T05:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/nykode-therapeutics-advances-ai-powered-immunotherapy-platform-with-strong-clinical-progress 2026-05-01T05:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-reports-strong-q1-growth-driven-by-cholesterol-drug-advances-weight-loss-drug-maritide-development 2026-05-01T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/precision-neuroscience-partners-with-uchicago-medicine-to-advance-brain-computer-interface-research-for-motor-function-restoration 2026-05-01T05:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-appoints-dr-annalisa-jenkins-as-strategic-adviser-to-advance-dendritic-cell-cancer-vaccine-platform 2026-05-01T01:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/mrm-health-s-mh002-receives-fda-fast-track-designation-for-ulcerative-colitis-treatment 2026-05-01T01:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-drug-companies-eye-ipos-and-private-funding-following-u-s-rescheduling-to-schedule-iii 2026-04-30T22:54:44+00:00 hourly 0.9 https://trial.medpath.com/news/arpa-h-awards-siemens-healthineers-60-million-to-develop-ultra-high-speed-photon-flash-radiotherapy 2026-04-30T22:53:24+00:00 hourly 0.9 https://trial.medpath.com/news/moleculent-secures-20-million-to-advance-cell-communication-mapping-technology 2026-04-30T22:52:17+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-initiates-phase-2-trial-for-novel-non-opioid-pain-therapy-cftx-1554 2026-04-30T22:51:30+00:00 hourly 0.9 https://trial.medpath.com/news/discontinuing-oac-after-af-catheter-ablation-reduces-bleeding-without-increasing-stroke-risk-alone-af-trial 2026-04-30T22:50:43+00:00 hourly 0.9 https://trial.medpath.com/news/engeneic-doses-first-patient-with-novel-egfr-targeted-nanocell-therapy-for-recurrent-glioblastoma 2026-04-30T22:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-appoints-cary-vance-as-permanent-ceo-following-successful-interim-leadership 2026-04-30T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-partners-with-nuvalent-in-multi-year-collaboration-for-precision-cancer-diagnostics 2026-04-30T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-acquires-replay-for-50-million-to-advance-hsv-gene-therapy-platform-for-rare-skin-diseases 2026-04-30T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/theradaptive-receives-fda-approval-to-advance-osteoadapt-sp-to-pivotal-phase-3-trial-for-spinal-fusion 2026-04-30T17:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-supraspacer-implant-for-irreparable-rotator-cuff-tears 2026-04-30T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-reports-strong-early-uptake-for-forzinity-in-barth-syndrome-treatment 2026-04-30T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-halts-newron-s-phase-iii-schizophrenia-trial-following-patient-death 2026-04-30T13:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/orchard-therapeutics-receives-innovation-passport-for-gene-therapy-otl-201-targeting-rare-sanfilippo-syndrome 2026-04-30T13:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-rhb-204-shows-comparable-antimicrobial-efficacy-to-rhb-104-in-crohn-s-disease-development 2026-04-30T13:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-infant-formula-safety-study-finds-low-contaminant-levels-amid-mounting-recall-concerns 2026-04-30T09:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-secures-9-9-million-in-gates-foundation-grants-to-advance-next-generation-tuberculosis-therapies 2026-04-30T09:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/syntara-raises-10-million-to-advance-amsulostat-phase-2b-trial-in-myelofibrosis 2026-04-30T09:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/formosa-pharmaceuticals-partners-with-singapore-eye-research-institute-to-develop-advanced-ophthalmic-formulations 2026-04-30T09:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/livzon-pharmaceutical-receives-regulatory-approval-for-brexpiprazole-microsphere-clinical-trial-in-adult-schizophrenia 2026-04-30T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/indian-patent-office-rejects-abbvie-patents-for-rinvoq-and-maviret-clearing-path-for-generic-competition 2026-04-30T05:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/parexel-acquires-ai-powered-pharmacovigilance-platform-vitrana-to-enhance-patient-safety-technology 2026-04-30T05:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/decade-long-study-reveals-common-knee-surgery-no-better-than-placebo-may-worsen-outcomes 2026-04-30T05:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/novel-radiotracer-shows-promise-for-non-invasive-endometriosis-diagnosis-in-phase-2-trial 2026-04-30T05:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-exercises-option-for-pinetree-s-first-in-class-egfr-degrader-in-500m-deal 2026-04-30T05:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/acrobiosystems-and-seromyx-systems-partner-to-advance-anti-cd20-monoclonal-antibody-research-through-comprehensive-functional-profiling 2026-04-30T05:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/vivacta-bio-secures-over-50-million-in-series-a-funding-to-advance-in-vivo-car-t-therapy-gt801 2026-04-30T05:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-denecimig-achieves-99-reduction-in-bleeding-episodes-for-hemophilia-a-patients-in-phase-3-trial 2026-04-30T01:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/acrux-advances-female-testosterone-therapy-to-phase-iii-for-hsdd-treatment 2026-04-30T01:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-mosaic-neo-mitral-valve-receives-fda-approval-launches-with-rapid-clinical-adoption 2026-04-30T01:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/circular-genomics-and-vitazi-ai-partner-to-develop-ai-powered-multimodal-alzheimer-s-detection-platform 2026-04-29T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/syncromune-s-sync-t-therapy-shows-87-response-rate-in-metastatic-prostate-cancer-phase-1-trial 2026-04-29T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/nivipit-trial-demonstrates-reduced-toxicity-with-intratumoral-anti-ctla4-in-metastatic-melanoma 2026-04-29T21:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/ema-launches-pilot-programme-for-breakthrough-medical-devices-and-ivds-in-q2-2026 2026-04-29T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/lts-lohmann-expands-cdmo-services-into-ophthalmic-drug-delivery-at-new-jersey-facility 2026-04-29T17:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/xtl-biopharmaceuticals-acquires-psyga-bio-to-create-leading-psychedelic-therapeutics-platform-following-trump-executive-order 2026-04-29T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-names-kunal-bhatia-as-cfo-to-scale-programmable-mrna-platform 2026-04-29T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/expression-therapeutics-receives-fda-fast-track-and-rare-pediatric-disease-designations-for-hemophilia-a-stem-cell-therapy 2026-04-29T17:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/hypervision-surgical-secures-ps17m-series-a-to-advance-ai-powered-hyperspectral-imaging-technology-for-surgery 2026-04-29T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/bd-launches-first-all-in-one-central-line-insertion-system-to-enhance-patient-safety 2026-04-29T17:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-data-systems-innovation-accelerates-cancer-drug-approvals-reducing-patient-wait-times 2026-04-29T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/zumutor-biologics-secures-7-3m-series-b-to-advance-first-in-class-nk-cell-checkpoint-therapy-zm008-into-phase-2 2026-04-29T13:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-reports-positive-24-month-data-for-votoplam-in-huntington-s-disease-extension-study 2026-04-29T13:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-s-sovleplenib-receives-priority-review-and-breakthrough-designation-in-china-for-rare-blood-disorder 2026-04-29T13:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/infinite-epigenetics-acquires-tally-health-in-largest-epigenetic-age-testing-deal 2026-04-29T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/mbiomics-completes-eur30m-series-a-to-advance-microbiome-cancer-co-therapy-toward-clinical-trials 2026-04-29T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-opens-flagship-u-s-bioprocess-design-center-to-accelerate-biologics-development 2026-04-29T05:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/creative-medical-technology-reports-93-response-rate-for-ultrasometm-in-knee-osteoarthritis-pilot-study 2026-04-29T01:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-first-generic-semaglutide-making-canada-first-g7-nation-to-authorize-glp-1-generic 2026-04-29T01:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-develops-see-cite-technology-to-enhance-precision-in-drug-discovery-and-protein-binding-analysis 2026-04-29T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-partnerships-transform-community-oncology-with-real-time-data-analytics-and-enhanced-clinical-trial-access 2026-04-29T01:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/new-york-s-food-safety-and-chemical-disclosure-act-a-state-level-overhaul-of-gras-regulation 2026-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kiniksa-raises-arcalyst-revenue-guidance-to-945-million-on-strong-q1-2026-pericarditis-sales 2026-04-28T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/asap-and-michael-j-fox-foundation-announce-261m-investment-to-advance-personalized-parkinson-s-treatments 2026-04-28T21:09:55+00:00 hourly 0.9 https://trial.medpath.com/news/uae-hospitals-pioneer-gene-therapy-for-spinal-muscular-atrophy-patients-across-age-groups 2026-04-28T21:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/anova-enterprises-reaches-500-urology-research-sites-in-digital-clinical-trial-network 2026-04-28T21:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/two-year-crenessity-data-shows-sustained-benefits-in-pediatric-and-adult-cah-patients 2026-04-28T21:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/double-bond-pharmaceutical-reports-5-6-month-survival-benefit-for-temodex-in-brain-tumor-study 2026-04-28T21:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/c-ray-therapeutics-secures-fda-approval-for-copper-64-drug-master-file-advancing-next-generation-pet-diagnostics 2026-04-28T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/ventripoint-s-ai-powered-cardiac-imaging-system-vms-4-0-submitted-for-expedited-regulatory-approval-in-china 2026-04-28T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-secures-patent-extension-for-vyndamax-through-2031-in-generic-settlement-deals 2026-04-28T21:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-real-time-clinical-trial-monitoring-pilot-with-astrazeneca-and-amgen-cancer-studies 2026-04-28T21:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-partners-with-ai-company-sciencemachine-to-accelerate-fabp5-inhibitor-development 2026-04-28T17:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/vensica-medical-receives-fda-ind-clearance-for-phase-2-trial-of-needle-free-botulinum-toxin-delivery-system-for-overactive-bladder 2026-04-28T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-laguna-diagnostics-blood-based-test-for-psychiatric-disorder-differentiation 2026-04-28T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/coultreon-biopharma-secures-125m-series-a-to-advance-novel-sik3-inhibitor-for-autoimmune-diseases 2026-04-28T17:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-receives-fda-clearance-for-ultreon-3-0-ai-powered-coronary-imaging-platform 2026-04-28T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/arcera-life-sciences-and-fosun-pharma-form-strategic-partnership-to-bridge-chinese-innovation-with-global-markets 2026-04-28T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/verified-clinical-trials-and-chubb-form-strategic-alliance-to-enhance-clinical-trial-safety-and-data-integrity 2026-04-28T17:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-reports-24-revenue-growth-in-q1-2026-driven-by-haematology-portfolio-and-altuvoct-ramp-up 2026-04-28T13:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/histoindex-expands-ai-driven-mash-diagnostic-network-with-new-texas-and-california-partnerships 2026-04-28T13:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-d-supplementation-shows-79-improvement-in-breast-cancer-chemotherapy-response 2026-04-28T13:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/carb-x-awards-2-6-million-to-adjane-for-gonorrhea-vaccine-development-using-nomv-platform 2026-04-28T13:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-partners-with-remepy-to-pioneer-hybrid-drugs-combining-pharmaceuticals-with-digital-therapeutics 2026-04-28T13:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/emergent-biosolutions-secures-50m-manufacturing-deal-for-type-1-diabetes-therapy-sab-142 2026-04-28T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/mark-cuban-s-cost-plus-drugs-partners-with-humana-to-transform-employer-prescription-benefits 2026-04-28T05:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-s-ibudilast-shows-promise-for-brain-metastasis-treatment-in-new-cnio-research 2026-04-28T05:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/konovo-experts-advocate-human-powered-ai-accelerated-approach-for-healthcare-panel-engagement 2026-04-28T01:45:32+00:00 hourly 0.9 https://trial.medpath.com/news/umoja-biopharma-unveils-industry-s-first-dual-targeted-bcma-x-gprc5d-in-vivo-car-t-therapy-for-multiple-myeloma 2026-04-28T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-to-present-preclinical-data-on-novel-in-vivo-car-t-therapy-sg293-at-asgct-2026 2026-04-28T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/pooled-cord-blood-stem-cell-product-achieves-96-survival-rate-in-blood-cancer-transplant-trial 2026-04-28T01:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/sunnybrook-health-sciences-centre-receives-41-million-donation-to-transform-clinical-trial-infrastructure-in-canada 2026-04-28T01:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/avenzo-therapeutics-initiates-cdk4-cdk2-dual-inhibitor-combination-trial-for-hr-her2-breast-cancer 2026-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dapsone-combination-therapy-reverses-alzheimer-s-biomarkers-in-chronic-lyme-disease-patient 2026-04-27T21:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/urine-biomarker-score-rail-shows-promise-in-predicting-lupus-nephritis-treatment-response 2026-04-27T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/angelini-pharma-announces-4-1-billion-acquisition-of-catalyst-pharmaceuticals-to-enter-us-rare-disease-market 2026-04-27T21:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/msk-researchers-uncover-pancreatic-cancer-cell-cooperation-mechanism-and-demonstrate-adc-efficacy-in-rare-pediatric-sarcoma 2026-04-27T21:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-drug-pipeline-reaches-10501-medicines-with-cancer-treatments-dominating-development 2026-04-27T21:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-advances-novel-t-cell-engager-hcw11-018b-for-solid-tumors-with-unique-cis-binding-mechanism 2026-04-27T17:13:52+00:00 hourly 0.9 https://trial.medpath.com/news/ligand-pharmaceuticals-acquires-xoma-royalty-for-739-million-expanding-portfolio-to-over-200-drug-assets 2026-04-27T17:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/blood-filtering-treatment-shows-promise-for-severe-early-preeclampsia-in-small-clinical-trial 2026-04-27T17:10:01+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-completes-phase-1-trial-of-bevemipretide-eye-drops-for-dry-amd 2026-04-27T17:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/uk-biotech-financing-rebounds-18-in-q1-2026-as-venture-capital-activity-surges 2026-04-27T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/apollomics-advances-c-met-inhibitor-vebreltinib-toward-fda-submission-following-strategic-turnaround 2026-04-27T17:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/pci-pharma-services-announces-1-billion-investment-in-us-manufacturing-expansion 2026-04-27T17:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/symptom-based-opioid-dosing-reduces-hospital-stay-for-newborns-with-withdrawal-syndrome 2026-04-27T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/sibel-health-secures-3-5-million-arpa-h-contract-to-develop-first-in-class-wearable-edema-monitor 2026-04-27T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/duvelisib-shows-promising-results-in-relapsed-refractory-peripheral-t-cell-lymphoma-phase-2-trial 2026-04-27T17:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/xcovery-partners-with-eversana-to-expand-commercial-launch-of-alk-positive-nsclc-drug-ensacove 2026-04-27T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-caplyta-for-schizophrenia-relapse-prevention-based-on-phase-iii-data 2026-04-27T17:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-show-promise-in-reducing-cancer-therapy-related-heart-damage 2026-04-27T13:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/cms-secures-exclusive-rights-to-market-advanced-intravenous-iron-therapies-in-china-through-15-year-partnership-with-pharmacosmos 2026-04-27T13:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/repurposed-drugs-show-promise-for-treating-aggressive-infant-leukemia-in-preclinical-studies 2026-04-27T13:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/courier-health-secures-50m-series-b-to-advance-ai-powered-patient-engagement-platform-for-specialty-therapies 2026-04-27T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/bd-and-suttons-creek-form-strategic-alliance-to-streamline-combination-product-development-for-pharma-and-biotech 2026-04-27T13:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-ajax-therapeutics-for-2-3-billion-to-advance-novel-jak2-inhibitor-for-blood-cancers 2026-04-27T13:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/intellia-s-crispr-gene-therapy-achieves-87-reduction-in-hereditary-angioedema-attacks-in-phase-3-trial 2026-04-27T13:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/motif-neurotech-receives-fda-approval-for-first-clinical-trial-of-wireless-brain-implant-for-treatment-resistant-depression 2026-04-27T13:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/cellenkos-receives-fda-clearance-for-phase-2-trial-of-ck0801-allogeneic-treg-therapy-in-aplastic-anemia 2026-04-27T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-first-national-parkinson-s-disease-translational-research-collaboration-to-accelerate-treatment-development 2026-04-27T13:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-biopharmaceuticals-secures-14m-to-advance-phase-3-osteoarthritis-trial-through-interim-analysis 2026-04-27T06:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/jw-pharmaceutical-completes-phase-3-dosing-for-gout-drug-epaminurad-in-multi-country-asian-trial 2026-04-27T06:30:07+00:00 hourly 0.9 https://trial.medpath.com/news/burosumab-shows-dramatic-mobility-gains-in-children-with-severe-fibrous-dysplasia 2026-04-27T06:30:02+00:00 hourly 0.9 https://trial.medpath.com/news/boan-biotech-advances-phase-ii-trial-for-novel-anti-cd25-antibody-combination-in-nsclc 2026-04-27T06:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-to-acquire-organon-for-11-75-billion-in-major-women-s-health-and-biosimilars-expansion 2026-04-27T06:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/dark-horse-consulting-group-forms-strategic-partnerships-to-accelerate-cell-and-gene-therapy-development-in-china 2026-04-27T03:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-england-relaunches-anti-smoking-pill-programme-with-generic-varenicline-and-new-cytisine-option 2026-04-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-secures-revised-dunkirk-manufacturing-deal-with-stricter-terms-and-40m-investment-commitment 2026-04-26T21:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-continues-real-world-study-of-refixia-in-japanese-hemophilia-b-patients 2026-04-26T21:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/pre-existing-antibodies-identified-as-key-barrier-to-phage-therapy-efficacy-in-landmark-australian-study 2026-04-26T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/nice-expands-access-to-astrazeneca-s-lokelma-as-hyperkalemia-treatment-threshold-lowered 2026-04-26T17:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioengineered-chewing-gum-shows-promise-against-cancer-linked-oral-microbes-in-head-and-neck-cancer-patients 2026-04-26T14:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/brii-bio-reports-durable-immunological-control-in-hepatitis-b-combination-therapy-analysis 2026-04-26T14:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/utah-biotech-startup-claims-breakthrough-in-lab-grown-human-sperm-technology 2026-04-26T09:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/mindy-brashears-returns-as-usda-under-secretary-for-food-safety-pledges-broader-salmonella-strategy 2026-04-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/repurposed-sleeping-sickness-drug-shows-promise-for-ultra-rare-bachmann-bupp-syndrome 2026-04-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-receives-phase-iii-approval-for-novel-anti-malarial-drug-zintrodiazine 2026-04-25T21:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/endoscopic-procedure-shows-promise-in-preventing-weight-regain-after-glp-1-drug-discontinuation 2026-04-25T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/berlin-heals-reports-positive-first-in-human-results-for-less-invasive-heart-failure-device-implantation 2026-04-25T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-review-of-three-psychedelic-drugs-for-depression-and-mental-health-treatment 2026-04-25T13:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-expands-medtech-portfolio-with-atraverse-medical-acquisition-and-viz-ai-partnership 2026-04-25T05:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/stony-brook-cancer-center-enrolls-patients-in-phase-3-breast-cancer-vaccine-trial-targeting-her2-positive-disease 2026-04-25T05:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/actg-launches-phase-2-trial-comparing-pramipexole-to-escitalopram-for-depression-and-cognitive-disorders-in-hiv-patients 2026-04-25T05:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/duke-margolis-convenes-public-workshop-to-advance-biomarker-use-in-fda-regulatory-review 2026-04-25T03:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/exploiting-a-new-weakness-in-zombie-like-senescent-cells-to-treat-cancer-and-age-associated-diseases 2026-04-25T01:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/russia-develops-gene-therapy-targeting-rage-receptor-to-combat-cellular-aging 2026-04-25T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/large-international-trial-shows-no-difference-between-fluid-types-for-pediatric-septic-shock-treatment 2026-04-25T01:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/frankfurt-court-upholds-arbitral-award-securing-besremi-access-for-polycythemia-vera-patients 2026-04-24T21:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/eight-year-study-confirms-long-term-safety-and-efficacy-of-tenofovir-alafenamide-for-chronic-hepatitis-b-in-chinese-patients 2026-04-24T21:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/entelo-bio-emerges-from-stealth-with-4m-to-advance-ai-driven-movement-disorder-therapeutics 2026-04-24T21:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/hansoh-biotech-presents-novel-bispecific-antibody-and-adc-research-at-aacr-2026 2026-04-24T21:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/plopii-files-patent-for-paraxanthine-based-headache-pill-to-replace-caffeine-in-otc-analgesics 2026-04-24T21:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-s-symbravo-shows-long-term-benefits-in-migraine-disability-and-quality-of-life 2026-04-24T21:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/arizona-launches-first-clinical-trial-using-whole-psilocybin-mushrooms-for-first-responder-ptsd-treatment 2026-04-24T21:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/africa-europe-partnership-launches-first-ever-clinical-trial-for-malaria-treatment-in-early-pregnancy 2026-04-24T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-opens-eur200-million-gene-therapy-manufacturing-facility-in-belgium 2026-04-24T17:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-reports-promising-results-for-crofelemer-in-rare-pediatric-intestinal-failure-conditions 2026-04-24T17:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/kurma-partners-closes-biofund-iv-at-eur215m-fueling-european-biotech-company-creation 2026-04-24T17:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-cancer-center-leads-global-phase-3-trial-testing-novel-parp-inhibitor-combination-for-brca-mutated-metastatic-breast-cancer 2026-04-24T15:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-and-pfizer-launch-eliquis-on-mark-cuban-s-cost-plus-drugs-platform 2026-04-24T13:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/ai-platform-identifies-traditional-chinese-medicine-compounds-for-alzheimer-s-disease-treatment 2026-04-24T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/biomede-trial-reveals-biomarker-driven-strategy-for-pediatric-brain-cancer-despite-missing-primary-endpoint 2026-04-24T13:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/zanubrutinib-shows-superior-real-world-survival-outcomes-compared-to-ibrutinib-in-relapsed-refractory-mantle-cell-lymphoma 2026-04-24T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-receives-positive-chmp-opinion-for-itvisma-gene-therapy-for-spinal-muscular-atrophy 2026-04-24T13:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-clarifies-semaglutide-status-in-canada-as-analysts-turn-cautious-biologics-facility-observations-in-focus 2026-04-24T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/ai-clinical-trial-market-projected-to-reach-54-7-billion-by-2030-as-industry-embraces-predictive-analytics 2026-04-24T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/biotia-launches-clinical-drug-resistance-testing-for-utis-following-validation-study 2026-04-24T09:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/tokyo-startup-seeks-approval-for-first-aim-based-drug-to-treat-chronic-kidney-disease-in-cats 2026-04-24T09:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-royalty-secures-modeyso-royalty-rights-following-strong-early-commercial-performance 2026-04-24T05:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/clinuvel-receives-ema-scientific-advice-for-pivotal-phase-iii-vitiligo-study-using-totality-of-evidence-approach 2026-04-24T05:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/nephrology-experts-outline-four-critical-strategies-to-improve-global-kidney-disease-trial-success-rates 2026-04-24T03:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/f2g-s-olorofim-shows-promise-in-high-risk-hematology-patients-with-invasive-aspergillosis 2026-04-24T01:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/freeze-dried-platelet-product-shows-promise-for-traumatic-brain-injury-treatment 2026-04-24T01:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-auvelity-for-alzheimer-s-disease-agitation-marking-second-approved-treatment-option 2026-04-24T01:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-abbvie-s-trenibote-wrinkle-treatment-over-manufacturing-issues 2026-04-24T01:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/hytn-innovations-spins-out-bpc-157-peptide-drug-development-business-for-ligament-disorders 2026-04-24T01:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-abbvie-s-novel-botulinum-toxin-trenibote-over-manufacturing-concerns 2026-04-24T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-persistent-divergence-in-global-regulatory-approaches-to-expedited-oncology-approvals 2026-04-24T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/uw-medicine-launches-clinical-trial-of-cnp-103-to-preserve-insulin-production-in-type-1-diabetes 2026-04-24T01:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-strikes-final-drug-pricing-deal-with-white-house-offers-free-gene-therapy-for-rare-hearing-loss 2026-04-23T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/tadv-procedure-shows-significant-quality-of-life-improvements-in-no-option-clti-patients 2026-04-23T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/theialife-appoints-thomas-ruggia-as-ceo-to-lead-phase-3-development-of-first-in-class-oral-myopia-therapy 2026-04-23T17:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/asciminib-shows-sustained-efficacy-in-heavily-pretreated-cml-patients-with-39-achieving-major-molecular-response 2026-04-23T17:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-sells-commercial-portfolio-to-apotex-for-100m-refocuses-on-orphan-drug-pipeline 2026-04-23T17:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/microneedle-biosensor-enables-real-time-drug-clearance-monitoring-and-early-detection-of-kidney-and-liver-dysfunction 2026-04-23T17:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-doses-first-patient-in-phase-2-3-trial-of-manganese-based-mri-contrast-agent 2026-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-reclassifies-cannabis-to-schedule-iii-opening-new-research-pathways 2026-04-23T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/recovery-trial-the-landmark-covid-19-study-that-saved-one-million-lives-worldwide 2026-04-23T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/repertoire-immune-medicines-initiates-first-in-human-trial-of-novel-tcr-bispecific-therapy-for-advanced-solid-tumors 2026-04-23T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/paxlovid-speeds-recovery-but-fails-to-reduce-hospitalizations-in-vaccinated-covid-19-patients 2026-04-23T05:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/federal-judge-allows-eli-lilly-lawsuit-against-compounded-tirzepatide-seller-to-proceed 2026-04-23T05:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-announces-plans-to-join-international-mrna-cancer-vaccine-clinical-trials-starting-2026 2026-04-23T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/prestige-biopharma-files-patent-for-novel-subcutaneous-antibody-delivery-platform-idc224 2026-04-23T05:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/certara-divests-regulatory-and-medical-writing-business-to-veristat-for-135-million-to-focus-on-ai-driven-drug-development 2026-04-23T01:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/xeltis-receives-eu-ce-mark-for-bioabsorbable-hemodialysis-graft-following-successful-120-patient-trial 2026-04-23T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/silo-pharma-targets-near-term-commercial-launch-of-ai-platform-as-ptsd-drug-spc-15-advances-toward-fda-engagement 2026-04-23T01:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-advances-polymer-testing-for-pnkp-inhibitor-technology-ahead-of-ind-enabling-studies 2026-04-22T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/six-year-old-girl-regains-vision-through-groundbreaking-nhs-gene-therapy-for-leber-s-congenital-amaurosis 2026-04-22T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-gene-therapy-trial-for-type-1-diabetes-to-begin-this-year-with-kriya-839 2026-04-22T21:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/10x-science-raises-4-8m-to-automate-protein-characterization-with-ai-platform 2026-04-22T21:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/evonik-invests-eur80-million-to-expand-biopharma-manufacturing-capacity-in-slovakia 2026-04-22T21:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-dh20931-shows-promise-against-triple-negative-breast-cancer-through-novel-lipid-targeting-mechanism 2026-04-22T21:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-anti-netrin-1-antibody-shows-promise-in-pancreatic-cancer-phase-1b-trial 2026-04-22T17:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/rafael-holdings-secures-exclusive-mit-license-for-cyclodextrin-therapy-targeting-apoe4-positive-alzheimer-s-patients 2026-04-22T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/demerx-receives-fda-clearance-for-novel-neuroplastogen-dmx-1001-to-treat-alcohol-use-disorder 2026-04-22T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/made-scientific-partners-with-regenicin-to-advance-novaderm-autologous-skin-substitute-toward-fda-approval 2026-04-22T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/mindera-health-receives-new-york-state-approval-for-mind-px-psoriasis-precision-medicine-test 2026-04-22T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-pegrizeprument-for-heart-transplant-rejection-prevention 2026-04-22T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-pharmaceuticals-acquires-kashiv-biosciences-for-750-million-to-create-global-biosimilar-leader 2026-04-22T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/united-laboratories-advances-dual-pipeline-with-fda-approval-for-tul321-and-china-approval-for-dupilumab-biosimilar 2026-04-22T17:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-opaganib-shows-promise-in-neuroblastoma-and-triple-negative-breast-cancer-preclinical-studies 2026-04-22T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/carob-concentrate-shows-promise-for-prediabetes-management-in-clinical-trial 2026-04-22T17:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/thryv-therapeutics-initiates-phase-2-3-trial-for-long-qt-syndrome-treatment-receives-fda-fast-track-designation 2026-04-22T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/aavantgarde-presents-interim-luce-1-trial-data-for-usher-syndrome-1b-gene-therapy-at-arvo-2026 2026-04-22T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-compete-for-8-billion-inhibrx-cancer-drug-that-could-enhance-keytruda 2026-04-22T13:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-s-lyt-200-shows-promising-results-in-phase-1b-trial-for-relapsed-refractory-blood-cancers 2026-04-22T13:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/hvivo-secures-landmark-phase-iii-whooping-cough-vaccine-trial-and-ps6m-influenza-drug-contract 2026-04-22T13:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/ractigen-s-rag-17-shows-81-reduction-in-neurodegeneration-biomarker-in-sod1-als-phase-i-trial 2026-04-22T09:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/calluna-pharma-completes-enrollment-in-phase-2-aurora-study-of-cal101-for-idiopathic-pulmonary-fibrosis 2026-04-22T09:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/dayspring-pharma-s-cg2001-foam-shows-50-efficacy-improvement-in-phase-ii-androgenetic-alopecia-trial 2026-04-22T09:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/neuro-symbolic-ai-shows-distinct-advantages-over-conventional-llms-for-mental-health-guidance 2026-04-22T07:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-advances-first-in-class-ibi363-to-pivotal-trials-for-immunotherapy-resistant-lung-cancer 2026-04-22T05:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/novi-health-s-hybrid-care-model-achieves-clinical-trial-level-weight-loss-in-real-world-glp-1-treatment 2026-04-22T05:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/rgenta-therapeutics-to-present-phase-1-clinical-data-on-rna-targeting-cancer-drug-rgt-61159-at-asco-2026 2026-04-22T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/sidra-medicine-becomes-first-hospital-in-qatar-to-offer-crispr-gene-therapy-for-sickle-cell-disease-and-thalassemia 2026-04-22T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/kyverna-s-car-t-therapy-for-stiff-person-syndrome-advances-to-bla-filing-based-on-natural-history-study 2026-04-22T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/digital-twins-emerge-as-breakthrough-in-rare-disease-research-certara-s-piet-van-der-graaf-explains 2026-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-led-studies-demonstrate-breakthrough-treatments-for-challenging-women-s-cancers 2026-04-21T21:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-nivolumab-shows-promise-for-precancerous-oral-lesions-in-phase-i-trial 2026-04-21T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/early-myocarditis-onset-after-immunotherapy-may-predict-treatment-related-fatality 2026-04-21T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/enspryng-achieves-68-reduction-in-mogad-relapses-in-pivotal-phase-iii-trial 2026-04-21T21:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-to-present-positive-phase-3-frontmind-data-for-tafasitamab-in-first-line-dlbcl-at-asco-2026 2026-04-21T21:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-expanded-indications-for-sinefix-orthopedic-implant-across-multiple-soft-tissue-repair-applications 2026-04-21T21:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/cerracap-ventures-invests-in-nephronomics-to-advance-ai-driven-kidney-disease-drug-discovery 2026-04-21T21:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-blood-collection-for-avertd-genetic-test-to-assess-opioid-use-disorder-risk 2026-04-21T21:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/aulos-bioscience-reports-promising-phase-1-2-results-for-ai-designed-melanoma-therapy-at-asco-2026 2026-04-21T17:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/crown-bioscience-and-turbine-partner-to-integrate-ai-driven-drug-discovery-with-organoid-validation-platform 2026-04-21T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/cemdisiran-achieves-breakthrough-results-in-phase-3-myasthenia-gravis-trial-positioning-for-first-sirna-approval 2026-04-21T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/gen1e-and-rubicon-research-form-strategic-partnership-to-advance-ai-driven-precision-medicine-platform 2026-04-21T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/minaris-achieves-100-manufacturing-success-rate-for-chimeric-therapeutics-cdh17-car-t-cancer-program 2026-04-21T17:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/bpgbio-appoints-former-oxford-innovation-chief-chas-bountra-as-cso-to-advance-mitochondrial-therapeutics-pipeline 2026-04-21T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/bioaegis-partners-with-prenosis-to-develop-ai-driven-precision-medicine-for-ards-treatment 2026-04-21T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-raises-2026-revenue-outlook-on-strong-nerlynx-demand-advances-alisertib-pipeline 2026-04-21T17:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/star-therapeutics-receives-fda-rare-pediatric-disease-and-breakthrough-therapy-designations-for-vga039-in-von-willebrand-disease 2026-04-21T17:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-health-launches-spire-platform-to-transform-post-approval-clinical-evidence-generation 2026-04-21T17:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/tortugas-neuroscience-emerges-from-stealth-with-106m-to-advance-cns-drug-pipeline-licensed-from-eisai-and-hansoh 2026-04-21T17:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-advances-ai-driven-heart-failure-monitoring-with-70-prediction-accuracy 2026-04-21T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/inbrain-completes-first-in-human-trial-of-graphene-brain-interface-with-no-safety-issues 2026-04-21T13:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-draft-guidance-on-fermentation-derived-antibiotics-sparks-industry-calls-for-global-harmonization 2026-04-21T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-launches-serif-biomedicines-with-50m-to-pioneer-modified-dna-therapeutics 2026-04-21T13:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/addex-gabab-pam-candidate-shows-promising-anti-cough-activity-in-non-human-primate-studies 2026-04-21T09:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/leinco-technologies-and-cellcarta-form-strategic-partnership-to-advance-proteomics-in-immuno-oncology-drug-development 2026-04-21T09:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/lirum-therapeutics-lx-101-shows-promising-preclinical-activity-in-ewing-sarcoma-advances-to-rapid-platform-trial 2026-04-21T05:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/controlling-ai-hallucinations-building-evidence-based-trust-in-clinical-and-scientific-workflows 2026-04-21T04:44:25+00:00 hourly 0.9 https://trial.medpath.com/news/conavi-medical-receives-fda-clearance-for-first-hybrid-ivus-oct-intravascular-imaging-system 2026-04-21T01:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-strengthens-contract-manufacturing-oversight-sets-new-quality-obligations-for-mahs-and-cmos 2026-04-21T01:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/rusan-pharma-secures-pmda-japan-gmp-approval-for-api-and-injectable-manufacturing-facilities 2026-04-21T01:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-to-present-clinical-update-on-ozekibart-in-late-line-colorectal-cancer 2026-04-21T01:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/lincotek-receives-fda-clearance-for-sportlinc-ankle-stabilization-device-targets-orthopedic-oem-market 2026-04-21T01:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/iu-led-coalition-secures-nsf-impact-engine-designation-to-accelerate-musculoskeletal-innovation 2026-04-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crexont-shows-superior-efficacy-in-phase-4-trial-delivering-over-3-additional-hours-of-daily-good-on-time-for-parkinson-s-patients 2026-04-20T22:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-publishes-first-peer-reviewed-validation-framework-for-ai-extracted-real-world-oncology-data 2026-04-20T22:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-lung-cancer-trials-consolidate-at-major-u-s-medical-centers-raising-access-concerns 2026-04-20T22:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/accord-biopharma-s-ustekinumab-biosimilar-imuldosa-gains-preferred-status-on-cigna-healthcare-formularies 2026-04-20T18:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/huxley-health-launches-aerasyn-biotech-division-secures-15m-financing-for-psychedelic-therapeutics-platform 2026-04-20T18:41:10+00:00 hourly 0.9 https://trial.medpath.com/news/abogen-s-mrna-encoded-t-cell-engager-abo2203-shows-promise-in-b-cell-lymphoma-with-superior-safety-profile 2026-04-20T18:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/viewsml-raises-4-9m-to-commercialize-ai-powered-virtual-biomarker-staining-technology 2026-04-20T18:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-jamp-pharma-s-golimumab-biosimilar-prupgolyv-for-autoimmune-diseases 2026-04-20T18:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/orion-pharma-s-odm-212-receives-fda-orphan-drug-designation-for-mesothelioma-treatment 2026-04-20T18:35:33+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-launches-ps150m-ai-accelerator-in-london-to-advance-drug-discovery 2026-04-20T18:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/sapience-therapeutics-reports-47-response-rate-for-first-in-class-b-catenin-antagonist-st316-in-second-line-colorectal-cancer 2026-04-20T18:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/st-david-s-south-austin-medical-center-enrolls-first-patient-globally-in-phase-iii-car-t-cell-trial-for-aggressive-large-b-cell-lymphoma 2026-04-20T18:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/jeeva-clinical-trials-acquires-clintelligence-ai-to-transform-clinical-trial-design-and-reduce-development-failures 2026-04-20T18:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-acquires-global-rights-to-felzartamab-with-850-million-deal-for-greater-china-assets 2026-04-20T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/toronto-ai-startup-biossil-raises-70m-to-resurrect-failed-drug-candidates-using-large-language-models 2026-04-20T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/chong-kun-dang-enrolls-first-u-s-patient-in-global-phase-1-2a-trial-of-adc-cancer-drug-ckd-703 2026-04-20T13:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-etavopivat-achieves-breakthrough-results-in-phase-3-sickle-cell-disease-trial 2026-04-20T13:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/deep-learning-and-brain-organoids-uncover-azole-antifungals-as-repurposable-drug-candidates-for-leigh-syndrome 2026-04-20T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-advances-commercial-scale-manufacturing-for-parkinson-s-gene-therapy-in-phase-ii-trial 2026-04-20T13:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-imaging-and-nyu-langone-health-form-strategic-alliance-to-advance-medical-imaging-innovation 2026-04-20T13:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/cellbxhealth-partners-with-royal-marsden-to-enhance-lung-cancer-treatment-through-ctc-dna-analysis 2026-04-20T13:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-receives-fda-approval-for-expanded-caldolor-indication-in-postoperative-pain-management 2026-04-20T09:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/penn-launches-18-million-ai-driven-rna-foundry-to-democratize-mrna-technology-beyond-vaccines 2026-04-20T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-t-cell-receptor-therapy-for-solid-tumors-in-synovial-sarcoma-patients 2026-04-20T09:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/hk-inno-n-partners-with-nextgen-to-advance-ipf-drug-nxc680-into-phase-1-clinical-trials 2026-04-20T05:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/nexalis-therapeutics-initiates-phase-2-trial-for-irx-211-in-breakthrough-cancer-pain 2026-04-20T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-treatment-reverses-accelerated-biological-aging-by-nearly-four-years-swiss-study-reveals 2026-04-20T01:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-kras-drug-shows-strong-results-at-aacr-2026 2026-04-20T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/xuanzhu-biopharma-s-diluoake-demonstrates-superior-efficacy-over-crizotinib-in-phase-iii-alk-positive-nsclc-trial 2026-04-19T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-confirms-consistent-efficacy-of-osteoporosis-biosimilar-obodence-across-diverse-patient-populations 2026-04-19T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-win-3-million-prize-for-breakthrough-research-leading-to-first-crispr-sickle-cell-therapy 2026-04-19T05:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-first-warning-letter-for-inappropriate-ai-use-in-drug-manufacturing 2026-04-19T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/biolamina-secures-eur20m-eib-loan-to-scale-laminin-technology-for-cell-therapy-manufacturing 2026-04-19T01:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/philadelphia-scientists-win-3-million-breakthrough-prize-for-first-fda-approved-gene-therapy-for-inherited-blindness 2026-04-19T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-se-s-drug-discovery-partnership-model-gains-traction-as-pharma-outsourcing-accelerates 2026-04-18T21:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/extended-immunotherapy-shows-safety-profile-in-rare-alveolar-soft-part-sarcoma-beyond-standard-two-year-treatment 2026-04-18T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-pressure-drug-candesartan-cilexetil-shows-promise-against-mrsa-infections-in-laboratory-study 2026-04-18T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-nuvaxovid-covid-19-vaccine-demonstrates-superior-tolerability-profile-compared-to-mrna-vaccine-in-head-to-head-study 2026-04-18T13:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/global-partners-back-africa-s-first-end-to-end-multi-vaccine-manufacturing-hub-in-south-africa 2026-04-18T09:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/model-medicines-secures-first-us-patent-for-ai-discovered-broad-spectrum-antiviral-mdl-001 2026-04-18T09:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/rznomics-rna-therapy-shows-23-complete-response-rate-in-liver-cancer-trial 2026-04-18T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/signant-health-acquires-ametris-to-create-integrated-ecoa-and-digital-biomarker-platform 2026-04-18T09:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/prame-directed-tcr-cell-therapy-achieves-deep-remission-in-pediatric-nephroblastoma-patient 2026-04-18T05:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/odyssey-therapeutics-files-for-232-million-nasdaq-ipo-to-advance-autoimmune-disease-pipeline 2026-04-18T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/asco-expands-tapur-study-with-first-antibody-drug-conjugate-and-braf-mek-inhibitor-combination 2026-04-18T01:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/biolojic-design-s-ai-designed-bd200-shows-superior-anti-tumor-activity-in-preclinical-studies-targeting-dual-cancer-antigens 2026-04-17T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/onconano-s-ph-sensitive-nanotechnology-platform-shows-promise-for-antigen-independent-cancer-drug-delivery 2026-04-17T21:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/waters-receives-fda-510-k-clearance-for-bd-bactec-fxi-culture-system-accelerating-bloodstream-infection-diagnostics 2026-04-17T21:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/shanghai-bao-pharmaceuticals-wins-nmpa-approval-to-begin-clinical-trials-of-world-s-first-recombinant-ulinastatin-bj044 2026-04-17T21:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/vosoritide-shows-promise-for-rare-genetic-growth-disorders-beyond-achondroplasia-in-phase-2-trial 2026-04-17T21:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/salubris-biotherapeutics-reports-promising-phase-1-2-data-for-5t4-targeted-adc-jk06-in-multiple-solid-tumors 2026-04-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-acquires-neurona-therapeutics-for-1-15-billion-to-advance-regenerative-cell-therapy-for-drug-resistant-epilepsy 2026-04-17T21:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-clinical-trial-shows-aerobic-exercise-lowers-long-term-cortisol-rewiring-stress-biology 2026-04-17T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/byondis-unveils-novel-adc-platforms-to-combat-cancer-drug-resistance-at-aacr-2026 2026-04-17T17:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/prmt5-inhibition-sensitizes-b-cell-lymphoma-to-ferroptosis-via-atf5-slc7a11-axis 2026-04-17T17:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/luxturna-gene-therapy-shows-functional-benefits-despite-structural-decline-in-real-world-study 2026-04-17T17:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-seeks-orphan-drug-designation-for-skinject-in-rare-gorlin-syndrome 2026-04-17T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-therapeutics-reports-confirmed-complete-responses-in-phase-2-trial-of-invikafusp-alfa-plus-trodelvy-for-metastatic-breast-cancer 2026-04-17T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/penetrium-bioscience-claims-breakthrough-in-tumor-microenvironment-targeting-to-overcome-cancer-drug-resistance 2026-04-17T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-led-trials-emerge-as-key-strategy-for-precision-psychiatry-development 2026-04-17T13:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/donor-derived-cell-therapy-enables-immunosuppression-withdrawal-in-liver-transplant-patients 2026-04-17T13:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/bioxodes-strengthens-clinical-advisory-board-and-advances-biox-101-pivotal-trial-for-intracerebral-hemorrhage 2026-04-17T13:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/merck-launches-first-pivotal-trial-of-cd19-t-cell-engager-mk-1045-against-blincyto-in-b-all 2026-04-17T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/naronapride-shows-statistically-significant-improvement-in-gastroparesis-symptoms-in-phase-2b-move-it-trial 2026-04-17T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-enstilar-foam-receives-nmpa-approval-for-plaque-psoriasis-treatment-in-china 2026-04-17T09:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/iran-war-exposes-medicine-pricing-s-deep-oil-vulnerability-methotrexate-costs-surge-up-to-87 2026-04-17T07:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-servier-launch-ai-driven-bispecific-antibody-engineering-team-in-france 2026-04-17T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/khondrion-initiates-pivotal-phase-3-trial-for-sonlicromanol-in-rare-mitochondrial-disease 2026-04-17T01:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/bio-protocol-launches-openlabs-platform-at-desci-berlin-merging-ai-with-decentralized-biotech-funding 2026-04-16T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-s-inb03-shows-promise-in-overcoming-her2-positive-breast-cancer-drug-resistance 2026-04-16T21:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-receives-fda-approval-for-generic-methotrexate-injection 2026-04-16T21:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-encourages-testosterone-therapy-manufacturers-to-pursue-expanded-indication-for-low-libido 2026-04-16T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-version-of-farxiga-for-type-2-diabetes-and-cardiovascular-disease 2026-04-16T21:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-launches-multi-cancer-study-of-quest-diagnostics-haystack-mrd-test-across-14-sites 2026-04-16T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-reacquires-gene-therapy-botaretigene-sparoparvovec-from-johnson-johnson-for-x-linked-retinitis-pigmentosa-treatment 2026-04-16T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharma-receives-clinical-trial-approvals-for-five-oncology-drugs-including-novel-kras-g12d-inhibitor 2026-04-16T21:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-researchers-uncover-nat10-myc-pathway-driving-immunotherapy-resistance-in-colorectal-cancer 2026-04-16T17:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/icer-calls-for-enhanced-transparency-in-fda-s-accelerated-approval-pathway 2026-04-16T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/latvian-study-reveals-77-long-term-cure-rate-for-multidrug-resistant-tuberculosis-far-exceeding-who-estimates 2026-04-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-reinstates-177-million-patent-verdict-for-teva-s-migraine-drug-ajovy-against-eli-lilly 2026-04-16T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/elephas-biosciences-and-mithrl-combine-real-time-tumor-profiling-with-ai-to-advance-immunotherapy-response-prediction 2026-04-16T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/revolune-launches-multiplex-immunofluorescence-reagents-partners-with-mindpeak-for-ai-powered-spatial-biology-workflow 2026-04-16T17:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/zyus-life-sciences-completes-phase-2a-utopia-1-trial-for-novel-non-opioid-cancer-pain-treatment 2026-04-16T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-secures-354-million-funding-for-cytisinicline-development-as-fda-review-continues 2026-04-16T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/roche-acquires-saga-diagnostics-for-595m-to-enhance-foundation-medicine-s-cancer-monitoring-portfolio 2026-04-16T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/mytomorrows-and-rare-disease-research-partner-to-streamline-clinical-trial-access-for-rare-disease-patients 2026-04-16T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/panthera-biopartners-expands-european-clinical-trial-network-with-hungarian-acquisition 2026-04-16T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/alethio-therapeutics-unveils-atx-011-first-in-class-mutation-agnostic-antibody-for-essential-thrombocythemia-treatment 2026-04-16T13:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/medera-receives-fda-fast-track-designation-for-gene-therapy-targeting-duchenne-muscular-dystrophy-associated-cardiomyopathy 2026-04-16T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/freya-biosciences-reports-positive-phase-1-results-for-fb301-in-ivf-related-embryo-implantation-failure 2026-04-16T13:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/trabectedin-irinotecan-combination-shows-promise-against-ews-fli1-fusion-in-ewing-sarcoma-phase-1-2-trial 2026-04-16T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/scirent-appoints-cardiac-electrophysiology-expert-prof-dr-wilhelm-haverkamp-as-chief-medical-officer 2026-04-16T13:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-s-theranym-biologics-expands-msd-partnership-with-175-million-mammalian-manufacturing-facility 2026-04-16T13:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-recalls-xanax-xr-3mg-tablets-nationwide-due-to-dissolution-failure 2026-04-16T09:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/storm-therapeutics-secures-56m-series-c-to-advance-first-in-class-mettl3-inhibitor-stc-15-in-phase-ii-sarcoma-trial 2026-04-16T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-showcases-next-generation-adc-and-t-cell-engager-data-at-asco-2026 2026-04-16T09:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-achieves-global-first-with-nmpa-acceptance-of-novel-lilrb4-cd3-bispecific-antibody-for-blood-cancers 2026-04-16T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-review-confirms-alzheimer-s-amyloid-targeting-antibodies-show-minimal-clinical-benefit-despite-plaque-clearance 2026-04-16T09:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-s-experimental-immunotherapy-shows-90-survival-improvement-in-glioblastoma-phase-i-trial 2026-04-16T05:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-accepts-mabwell-s-supplemental-application-for-denosumab-biosimilar-maiweijian-to-prevent-skeletal-events-in-cancer-patients 2026-04-16T05:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/orvida-pharma-reports-positive-phase-1a-safety-data-for-km-023-first-in-class-trpv3-inhibitor-for-olmsted-syndrome 2026-04-16T01:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/elion-therapeutics-initiates-phase-2-trial-of-turletricin-for-invasive-mould-infections 2026-04-16T01:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/clearnote-health-s-avantect-pancreatic-cancer-test-achieves-82-6-sensitivity-in-early-detection 2026-04-16T01:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/alivecor-receives-ce-mark-for-portable-12-lead-ecg-system-with-ai-powered-cardiac-detection 2026-04-16T01:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-in-pact-av-drug-coated-balloon-shows-sustained-real-world-efficacy-in-dialysis-patients 2026-04-16T01:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/biologics-show-lower-ocular-disease-risk-in-psoriasis-patients-compared-to-conventional-therapies 2026-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/replimune-lays-off-200-employees-following-second-fda-rejection-of-melanoma-treatment-rp1 2026-04-15T23:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotech-s-immunocytokine-adc-shows-78-response-rate-in-colorectal-cancer-trial 2026-04-15T23:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-to-eliminate-alternative-payment-pathway-for-breakthrough-medical-devices 2026-04-15T23:22:11+00:00 hourly 0.9 https://trial.medpath.com/news/litmys-and-konovo-form-strategic-partnership-to-transform-drug-development-intelligence 2026-04-15T17:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/dutch-drup-trial-demonstrates-significant-potential-for-off-label-cancer-drug-use-in-advanced-patients 2026-04-15T17:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/oncohost-unveils-proteomic-aging-biomarkers-for-immunotherapy-response-prediction-at-aacr-2026 2026-04-15T17:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/filana-therapeutics-simufilam-shows-dose-dependent-seizure-reduction-in-tuberous-sclerosis-complex-mouse-model 2026-04-15T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/nucleai-and-sirona-dx-form-strategic-partnership-to-advance-spatial-proteomics-in-drug-development 2026-04-15T17:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/sanyou-bio-launches-14-day-antibody-discovery-workflow-compressing-lead-molecule-identification-from-months-to-two-weeks 2026-04-15T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/penn-state-launches-phase-ii-trial-of-dfmo-for-pediatric-bone-cancers-following-fda-approval-in-neuroblastoma 2026-04-15T17:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/fifty-1-labs-advances-ai-powered-peptide-biotechnology-platform-targeting-musculoskeletal-health 2026-04-15T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-rapiblyk-for-pediatric-supraventricular-tachycardia-marking-first-u-s-treatment-option 2026-04-15T17:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/biognosys-partners-with-michael-j-fox-foundation-to-develop-critical-lrrk2-biomarker-assays-for-parkinson-s-disease 2026-04-15T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/beeline-medicines-emerges-with-300m-series-a-and-bristol-myers-immune-disease-pipeline 2026-04-15T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/proteomic-blood-test-predicts-kidney-failure-in-apol1-high-risk-individuals-years-before-symptoms-emerge 2026-04-15T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/atelerix-expands-hydrogel-cell-preservation-technology-through-middle-east-partnership-and-new-organoid-solution 2026-04-15T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-launches-first-fda-cleared-rapid-fentanyl-test-made-in-us-delivers-results-in-10-minutes 2026-04-15T13:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/arbutus-receives-fda-fast-track-designation-for-hepatitis-b-rnai-therapeutic-imdusiran 2026-04-15T13:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/c-mo-medical-solutions-receives-ce-mark-for-ai-powered-cough-monitoring-system 2026-04-15T13:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/yellowbird-diagnostics-initiates-first-in-human-trial-of-novel-inflammation-imaging-agent-neucavis 2026-04-15T13:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-invests-in-restore-vision-s-gene-therapy-for-retinal-blindness-through-first-cvc-deal 2026-04-15T13:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/two-phase-2-trials-fail-to-demonstrate-cognitive-benefits-in-schizophrenia-despite-different-mechanisms 2026-04-15T13:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/isofol-medical-expands-phase-ib-ii-trial-for-arfolitixorin-in-colorectal-cancer-following-german-regulatory-approval 2026-04-15T13:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/synusight-s-sst001-a-synuclein-pet-tracer-receives-nmpa-approval-for-phase-i-clinical-trial-in-china 2026-04-15T05:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-on-next-generation-sequencing-for-gene-therapy-safety-assessment 2026-04-15T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-suzhou-biosafety-testing-center-earns-fourth-ema-gmp-certification-enabling-19-biologics-for-eu-market 2026-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vasa-therapeutics-partners-with-lilly-tunelab-to-accelerate-ai-driven-camkii-inhibitor-development 2026-04-14T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/toby-s-urine-based-multi-cancer-detection-test-receives-fda-breakthrough-device-designation 2026-04-14T21:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-reports-promising-early-results-for-padeliporfin-vtp-in-pancreatic-cancer-eyes-strategic-partnerships 2026-04-14T21:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-launches-withzeta-ai-world-s-first-multi-agentic-ai-co-scientist-for-rare-cancer-drug-discovery 2026-04-14T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/obsidian-and-galera-therapeutics-announce-350-million-merger-to-advance-next-generation-til-cell-therapy 2026-04-14T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/rivus-pharmaceuticals-initiates-phase-ii-amplify-trial-for-hu6-in-mash-treatment 2026-04-14T21:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-crossbridge-bio-for-up-to-300-million-to-advance-dual-payload-adc-technology 2026-04-14T21:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/hinge-bio-initiates-first-in-human-trial-of-hb2198-novel-dual-target-b-cell-depleting-therapy-for-autoimmune-diseases 2026-04-14T21:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/phrontline-biopharma-s-tj106-shows-promise-against-her2-low-and-adc-resistant-tumors-in-preclinical-studies 2026-04-14T21:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/vectorbuilder-launches-mutefree-aav-technology-to-solve-itr-instability-in-gene-therapy-manufacturing 2026-04-14T21:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-experience-with-revakinagene-taroretcel-lwey-encelto-for-mactel-first-year-insights-on-patient-selection-and-surgical-technique 2026-04-14T21:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-reports-first-clinical-data-from-mythic-trial-combining-wee1-and-pkmyt1-inhibitors-at-aacr-2026 2026-04-14T21:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/medline-recalls-angiographic-syringes-after-fda-warning-over-life-threatening-disconnection-risk 2026-04-14T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/hibercell-s-hc-7366-shows-promise-in-late-line-renal-cell-carcinoma-with-37-response-rate-in-phase-1b-trial 2026-04-14T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-analysis-reveals-immune-dynamics-of-moderna-covid-19-vaccine-in-pregnant-women 2026-04-14T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/birmingham-receives-ps10m-to-build-advanced-biomanufacturing-facility-for-cell-and-gene-therapies 2026-04-14T13:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/hainan-s-boao-lecheng-pilot-zone-slashes-drug-approval-to-1-6-days-transforming-rare-disease-access 2026-04-14T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-guidance-and-regulatory-uncertainty-create-challenges-for-us-biosimilar-market-development 2026-04-14T13:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/adcendo-secures-75-million-series-c-to-advance-first-in-class-adc-pipeline-for-high-unmet-need-cancers 2026-04-14T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/huons-biopharma-secures-kuwait-approval-for-hutox-botulinum-toxin-accelerates-middle-east-expansion 2026-04-14T13:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/artcline-completes-patient-recruitment-for-septic-shock-immune-cell-therapy-trial 2026-04-14T13:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/memorial-health-joins-national-clinical-trial-testing-advanced-feeding-tube-system-for-premature-infants 2026-04-14T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/asgard-therapeutics-appoints-veteran-oncologist-as-cmo-to-advance-novel-cancer-immunotherapy-at-108 2026-04-14T09:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/panntherapi-advances-phase-2a-trial-for-rare-epilepsy-drug-pti5803-targeting-pannexin-1-channel 2026-04-14T09:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/ailux-appoints-former-astrazeneca-executive-maria-belvisi-as-chief-scientific-officer-to-lead-drug-development-strategy 2026-04-14T09:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-daretabart-for-high-risk-neuroblastoma-treatment 2026-04-14T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/protaryx-medical-receives-fda-510-k-clearance-for-transseptal-puncture-device 2026-04-14T05:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/eclipse-life-sciences-completes-enrollment-in-phase-2-trial-of-ec-104-for-diabetic-macular-edema 2026-04-14T01:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-2200-notices-to-companies-and-researchers-over-unpublished-clinical-trial-results 2026-04-14T01:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/scripps-health-receives-12-7-million-grant-to-develop-scaffold-free-stem-cell-therapy-for-knee-cartilage-repair 2026-04-14T01:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/veld-pharmaceuticals-partners-with-chiesi-to-launch-rare-disease-access-program-across-africa 2026-04-14T01:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-sets-first-drug-price-cap-on-diabetes-medication-jardiance-at-204-per-month 2026-04-13T21:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/bioora-partners-with-cincinnati-children-s-to-advance-next-generation-car-t-therapy-for-pediatric-leukemia 2026-04-13T21:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-trastuzumab-deruxtecan-improves-five-year-survival-in-her2-positive-metastatic-colorectal-cancer 2026-04-13T21:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/ohsu-receives-9-2-million-nih-funding-to-develop-advanced-organs-on-chips-for-bone-cancer-research 2026-04-13T21:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-secures-745m-licensing-deal-with-haisco-for-pain-pipeline-assets 2026-04-13T21:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/airway-therapeutics-strengthens-board-with-cormedix-ceo-joe-todisco-as-zelpultide-alfa-advances 2026-04-13T21:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/nih-sponsored-trial-shows-stent-placement-significantly-reduces-post-thrombotic-syndrome-severity 2026-04-13T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/frontier-medicines-appoints-former-seagen-ceo-david-epstein-to-board-as-company-advances-covalent-precision-medicine-pipeline 2026-04-13T17:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-plans-reclassification-of-diagnostic-endoscopic-light-source-systems-used-in-bladder-cancer-detection 2026-04-13T17:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-therapeutics-initiates-phase-1-trial-of-akb-9090-for-cardiac-surgery-associated-acute-kidney-injury 2026-04-13T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/norwegian-oslo-patient-achieves-hiv-remission-following-stem-cell-transplant-with-rare-genetic-mutation 2026-04-13T15:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/prosomnus-receives-fda-clearance-for-first-theragnostic-sleep-apnea-device-combining-oral-therapy-with-continuous-monitoring 2026-04-13T13:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/korea-university-moderna-mrna-hantavirus-vaccine-stalls-as-funding-shortfall-blocks-clinical-trials 2026-04-13T13:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/duke-university-clinical-trial-shows-promise-for-immunotherapy-as-first-line-treatment-in-colorectal-cancer 2026-04-13T13:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/haisco-partners-with-abbvie-in-745-million-pain-therapy-licensing-deal 2026-04-13T13:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/os-therapies-strengthens-strategic-advisory-board-with-industry-luminaries-craig-eagle-and-robert-langer 2026-04-13T13:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/spyre-therapeutics-spy001-demonstrates-promising-efficacy-in-phase-2-ulcerative-colitis-trial 2026-04-13T13:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/roche-receives-ce-mark-for-elecsys-nfl-blood-test-to-monitor-multiple-sclerosis-neuroinflammation 2026-04-13T13:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/acucort-reaches-fda-agreement-on-pediatric-study-plan-for-zeqmelit-r-clearing-path-toward-us-nda-submission 2026-04-13T09:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/synox-therapeutics-reports-positive-phase-3-results-for-emactuzumab-in-tenosynovial-giant-cell-tumor 2026-04-13T09:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/st-pharm-secures-first-japanese-patent-for-mrna-lnp-platform-technology-stp1244 2026-04-13T05:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/hlb-life-science-r-d-secures-two-major-government-r-d-projects-worth-6-2-million-for-ai-oncology-and-medical-cannabis-development 2026-04-13T05:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/yuhan-s-yh35995-receives-fda-orphan-drug-designation-for-gaucher-disease-treatment 2026-04-13T05:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/zeto-receives-fda-clearance-for-new-wave-eeg-system-to-address-outpatient-neurodiagnostic-delays 2026-04-13T05:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/telix-and-regeneron-form-2-1-billion-strategic-partnership-to-develop-next-generation-radiopharmaceuticals 2026-04-13T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-b7h3-antibody-drug-conjugate-shows-strong-efficacy-in-cervical-and-ovarian-cancers 2026-04-13T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/miracell-receives-fda-510-k-clearance-for-smart-m-cell-stem-cell-extraction-system 2026-04-12T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-nanodisc-platform-reveals-hidden-viral-vulnerabilities-for-hiv-and-ebola-vaccine-development 2026-04-12T17:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-diagnostic-testing-and-new-antibiotics-fail-to-reduce-deaths-from-drug-resistant-infections 2026-04-12T14:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-discontinues-brensocatib-development-for-hidradenitis-suppurativa-after-phase-2b-trial-failure 2026-04-11T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/cartherics-expands-catalent-partnership-and-secures-japanese-patent-for-off-the-shelf-car-nk-cell-therapies 2026-04-11T21:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-bioscience-partners-with-unicancer-to-explore-phase-3-trial-for-pancreatic-cancer-drug-mitazalimab 2026-04-11T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/letrozole-shows-promise-in-improving-ivf-success-rates-for-poor-ovarian-responders 2026-04-11T17:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/hanx-biopharmaceuticals-presents-four-innovative-cancer-therapies-at-2026-aacr-annual-meeting 2026-04-11T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/korea-university-and-mfc-partner-to-develop-muscle-loss-therapeutics-for-space-missions 2026-04-11T09:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/hemab-therapeutics-files-for-nasdaq-ipo-to-advance-bleeding-disorder-therapies 2026-04-11T01:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-pharmaceuticals-launches-generic-bimatoprost-for-glaucoma-treatment 2026-04-10T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/three-novel-therapies-target-frail-hnscc-patients-unable-to-tolerate-standard-treatment 2026-04-10T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/vivatides-therapeutics-raises-54-million-series-a-to-advance-extrahepatic-rna-therapeutics-platform 2026-04-10T21:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/sylvester-cancer-center-tests-novel-virus-immunotherapy-combination-for-aggressive-neuroendocrine-tumors 2026-04-10T21:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-as-a-pathway-not-a-last-resort-the-evolving-landscape-of-ovarian-cancer-research 2026-04-10T21:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-pharmaceuticals-leverages-glp-1-manufacturing-partnership-with-pfizer-to-expand-beyond-traditional-generics 2026-04-10T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/canada-invests-50-million-to-build-critical-medicines-production-centre-in-alberta 2026-04-10T17:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/ai-analysis-of-reddit-posts-reveals-unreported-glp-1-drug-side-effects-including-reproductive-and-temperature-symptoms 2026-04-10T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-bio-partners-with-instituto-butantan-to-bring-car-t-cell-therapy-to-brazil-s-public-health-system 2026-04-10T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/yeast-beta-glucan-supplement-reprograms-bone-marrow-stem-cells-to-restore-anti-tumor-immunity-in-obesity 2026-04-10T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-urgent-safety-alert-for-cenobamate-following-severe-liver-injury-reports 2026-04-10T17:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/severe-enterocolitis-emerges-as-rare-but-fatal-complication-of-bcma-car-t-therapy 2026-04-10T17:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/realta-secures-40m-to-advance-first-in-class-therapy-for-fatal-neonatal-brain-injury 2026-04-10T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-to-present-updated-darlifarnib-combination-data-for-renal-cell-carcinoma-at-ikcs-europe-2026 2026-04-10T13:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/ailsynbio-and-dong-e-e-jiao-partner-to-advance-ai-driven-traditional-chinese-medicine-research 2026-04-10T13:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-acting-director-delays-publication-of-study-showing-covid-19-vaccine-effectiveness 2026-04-10T13:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-bispecific-antibody-tarlatamab-receives-china-approval-for-small-cell-lung-cancer 2026-04-10T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/france-becomes-first-nation-to-approve-iv-ketamine-for-acute-suicidal-crisis 2026-04-10T13:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-completes-direct-listing-transition-on-nasdaq-exchanges-all-adss-for-ordinary-shares 2026-04-10T09:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/neuland-laboratories-appoints-new-ceo-and-managing-director 2026-04-10T05:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-initiates-first-in-human-trial-of-novel-long-acting-influenza-drug-ak0406-in-australia 2026-04-10T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/premature-menopause-linked-to-40-higher-lifetime-risk-of-coronary-heart-disease-landmark-study-finds 2026-04-10T03:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/allrock-bio-initiates-phase-iia-trial-of-first-in-class-oral-rock-inhibitor-for-pulmonary-hypertension 2026-04-10T01:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/nextbiomedical-secures-exclusive-japan-distribution-deal-for-nexsphere-f-embolization-device 2026-04-10T01:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/nmg-secures-297-million-financing-package-to-advance-graphite-mining-operations-for-battery-materials 2026-04-10T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biotherapeutics-partners-with-bristol-myers-squibb-to-develop-next-generation-t-cell-engagers-for-solid-tumors 2026-04-09T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-waterloo-study-shows-natural-compounds-enhance-alzheimer-s-antibody-therapies 2026-04-09T21:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/champions-oncology-to-present-eight-studies-on-predicting-cancer-drug-response-at-aacr-2026 2026-04-09T21:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/galenusrx-and-clutch-health-form-strategic-partnership-to-enhance-complex-patient-care-through-precision-medicine-and-behavioral-incentives 2026-04-09T21:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-achieves-hkex-milestone-with-b-marker-removal-advances-global-adc-pipeline 2026-04-09T21:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/deepcyte-secures-1-5m-seed-funding-to-advance-ai-powered-single-cell-toxicology-platform 2026-04-09T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/covar-receives-darpa-contract-to-develop-ai-system-for-medical-decision-making-enhancement 2026-04-09T21:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/merck-discontinues-in-house-trop2-adc-mk-6837-after-revealing-dual-development-strategy 2026-04-09T21:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/click-therapeutics-secures-50m-series-d-to-commercialize-breakthrough-digital-therapeutic-for-schizophrenia 2026-04-09T17:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/byondis-appoints-christoph-korpus-as-ceo-to-lead-adc-technology-platform-development 2026-04-09T17:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/rani-therapeutics-strengthens-leadership-team-with-key-strategic-appointments-to-advance-oral-biologics-platform 2026-04-09T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-receives-fda-approval-for-generic-progesterone-vaginal-inserts-in-59-2-million-market 2026-04-09T17:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-acquires-market-authorization-for-nuvaxovid-covid-19-vaccine-in-canada 2026-04-09T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/oncoc4-initiates-first-in-class-anti-siglec-10-antibody-trial-for-alzheimer-s-disease-treatment 2026-04-09T17:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/granules-india-implements-digital-overhaul-following-fda-warning-over-manufacturing-violations 2026-04-09T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-achieves-world-first-simultaneous-remission-of-three-autoimmune-diseases 2026-04-09T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/alpheus-medical-launches-phase-2b-trial-for-novel-glioblastoma-therapy-using-ultrasound-activated-drug-approach 2026-04-09T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/sparian-biosciences-initiates-phase-1-trial-of-sbs-147-novel-oral-pain-drug-targeting-opioid-alternative 2026-04-09T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-and-seer-partner-with-singapore-s-precise-sg100k-for-large-scale-proteomics-study 2026-04-09T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/boston-oncology-secures-100m-licensing-deal-for-chinese-cancer-drugs-in-middle-east-and-north-africa 2026-04-09T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-achieves-complete-remission-in-woman-with-three-simultaneous-autoimmune-diseases 2026-04-09T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-presents-new-epidiolex-behavioral-data-at-aan-2026-demonstrating-impact-beyond-seizure-control 2026-04-09T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/cures-within-reach-funds-five-drug-repurposing-trials-in-chicago-to-address-unmet-medical-needs 2026-04-09T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-develops-brain-penetrating-aramchol-formulation-for-parkinson-s-disease-and-synucleinopathies 2026-04-09T17:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-s-vp-315-shows-promising-abscopal-effect-in-basal-cell-carcinoma-phase-2-trial 2026-04-09T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/brd2-emerges-as-key-driver-of-bet-inhibitor-resistance-across-multiple-cancers 2026-04-09T13:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4-therapeutics-and-roche-expand-partnership-with-1-billion-dac-collaboration 2026-04-09T13:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-exercises-option-for-kymera-s-kt-200-cdk2-degrader-triggering-45m-milestone-payment 2026-04-09T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/bdc-launches-150-million-life-sciences-venture-fund-to-address-early-stage-funding-gap-in-canada 2026-04-09T13:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-car-t-therapy-for-solid-tumors-set-to-launch-in-china 2026-04-09T09:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/sbp-group-s-m701-bispecific-antibody-receives-nda-acceptance-for-malignant-ascites-treatment 2026-04-09T06:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/triple-combination-pill-reduces-recurrent-stroke-risk-by-39-in-landmark-trident-trial 2026-04-09T05:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/virica-biotech-and-fujifilm-biosciences-partner-to-enhance-aav-production-for-gene-therapy-manufacturing 2026-04-09T01:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-medicine-launches-first-of-its-kind-compact-proton-therapy-system-treats-first-pediatric-patient 2026-04-09T01:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-partners-with-ginkgo-bioworks-to-accelerate-ai-driven-rna-editing-drug-discovery 2026-04-09T01:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-secures-25-5m-barda-contract-for-emergency-burn-treatment-preparedness 2026-04-09T01:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/neuroclues-secures-eur10-million-series-a-to-scale-ai-powered-eye-movement-biomarkers-for-neurological-diagnosis 2026-04-09T01:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-digital-health-partners-with-enable-injections-to-develop-companion-digital-solution-for-enfuse-r-on-body-delivery-system 2026-04-09T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-anti-cd38-therapy-mezagitamab-achieves-91-response-rate-in-immune-thrombocytopenia-phase-ii-trial 2026-04-09T01:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funded-team-based-care-model-achieves-significant-blood-pressure-reduction-in-underserved-populations 2026-04-09T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-initiates-thetis-trial-testing-nereus-for-glp-1-receptor-agonist-induced-vomiting 2026-04-09T01:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/modular-medical-launches-patient-website-for-pivot-tubeless-insulin-patch-pump-following-fda-clearance 2026-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tavapadon-shows-promise-for-parkinson-s-disease-treatment-in-phase-3-trials 2026-04-08T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-licenses-ai-designed-aav-capsid-from-dyno-therapeutics-for-skeletal-muscle-gene-therapy 2026-04-08T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/remedy-plan-therapeutics-strengthens-leadership-with-appointment-of-jotin-marango-as-cfo-and-cbo 2026-04-08T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/fshd-society-launches-industry-collaborative-to-accelerate-clinical-trial-development-for-rare-muscular-dystrophy 2026-04-08T21:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/suven-s-ropanicant-meets-primary-endpoint-in-phase-2b-trial-for-major-depressive-disorder 2026-04-08T21:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/trogenix-s-gene-therapy-achieves-83-complete-tumor-elimination-in-glioblastoma-model-nature-study-shows 2026-04-08T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/tae-life-sciences-achieves-100-complete-response-rate-in-head-and-neck-cancer-with-novel-bnct-platform 2026-04-08T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/transformer-base-editor-shows-promise-in-first-clinical-trial-for-b-thalassaemia-treatment 2026-04-08T21:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/spermosens-advances-juno-checked-generation-3-fertility-diagnostic-system-through-clinical-validation 2026-04-08T21:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-cdmo-facilities-achieve-major-manufacturing-milestones-as-biologics-production-capacity-expands 2026-04-08T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/23andme-identifies-genetic-variants-that-predict-glp-1-drug-response-and-side-effects 2026-04-08T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/bioporto-divests-antibody-business-for-10-5m-to-focus-on-ngal-biomarker-development 2026-04-08T17:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/sidewinder-therapeutics-raises-137m-series-b-to-advance-next-generation-bispecific-adcs-for-cancer-treatment 2026-04-08T17:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/organogenesis-puraply-am-shows-significant-efficacy-in-diabetic-foot-ulcer-trial 2026-04-08T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-appoints-david-a-brown-as-chief-scientific-officer-to-advance-mitochondrial-medicine-pipeline 2026-04-08T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/cortec-receives-fda-breakthrough-device-designation-for-brain-computer-interface-in-stroke-rehabilitation 2026-04-08T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/swedish-government-invests-in-precision-medicine-cancer-studies-focu-se-and-sprintr-receive-major-funding 2026-04-08T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/duloxetine-fails-to-prevent-oxaliplatin-induced-peripheral-neuropathy-in-colorectal-cancer-patients 2026-04-08T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/modex-therapeutics-initiates-phase-1-trial-of-novel-tetravalent-covid-19-prevention-antibody-mdx2301 2026-04-08T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-gene-silencing-drug-biib094-shows-promise-in-first-parkinson-s-disease-trial 2026-04-08T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-radiesse-for-decollete-wrinkle-treatment-marking-first-biostimulator-for-face-and-body-use 2026-04-08T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-s-geography-problem-why-approval-doesn-t-equal-access 2026-04-08T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/supira-medical-receives-fda-approval-for-support-ii-pivotal-trial-of-next-generation-percutaneous-ventricular-assist-device 2026-04-08T17:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/waters-receives-fda-clearance-for-at-home-cervical-cancer-screening-kit 2026-04-08T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-pharma-s-novel-dual-mechanism-drug-tinostamustine-enters-phase-2-3-trial-for-glioblastoma 2026-04-08T17:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/incyclix-bio-secures-5m-series-b-extension-to-advance-cdk2-inhibitor-inx-315-in-resistant-breast-and-ovarian-cancers 2026-04-08T13:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/ani-pharmaceuticals-receives-fda-approval-for-generic-isosorbide-mononitrate-tablets 2026-04-08T13:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/hku-and-grand-pharmaceutical-form-strategic-partnership-to-develop-novel-anti-infective-therapies 2026-04-08T13:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/jeito-capital-closes-record-1-2-billion-fund-to-accelerate-european-biopharma-innovation 2026-04-08T09:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/metallium-secures-1m-pentagon-phase-ii-contract-for-critical-metal-recovery-technology 2026-04-08T09:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/route-92-medical-secures-50-million-growth-financing-to-expand-revolutionary-stroke-treatment-technology 2026-04-08T09:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/roosterbio-partners-with-minebio-to-expand-msc-and-exosome-manufacturing-solutions-in-china 2026-04-08T09:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/huons-meditech-secures-nmpa-approval-for-premium-9pin-needle-in-china-s-aesthetic-market 2026-04-08T09:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-secures-482-million-barda-contract-to-strengthen-u-s-biodefense-against-drug-resistant-bacterial-threats 2026-04-08T09:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/methylscan-blood-test-achieves-93-8-accuracy-in-detecting-four-cancer-types-through-novel-dna-methylation-analysis 2026-04-08T05:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-mimics-exercise-benefits-in-prostate-cancer-patients-through-metabolic-pathway-activation 2026-04-08T05:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/neurotherapia-completes-phase-2a-trial-of-ntrx-07-for-alzheimer-s-disease-demonstrates-safety-and-target-engagement 2026-04-08T05:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-firms-shift-fda-approved-drug-manufacturing-to-europe-despite-us-tariffs-widening-outsourcing-gap-to-historic-levels 2026-04-08T03:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-drug-gatc-1021-shows-promise-for-opioid-use-disorder-in-landmark-pnas-study 2026-04-08T01:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/novel-actinium-225-radioconjugate-shows-promise-against-treatment-resistant-her2-positive-breast-cancer 2026-04-08T01:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-s-cefiderocol-shows-68-clinical-cure-rate-against-highly-resistant-mbl-producing-enterobacterales-in-real-world-study 2026-04-08T01:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/salk-institute-receives-41-3m-arpa-h-award-to-advance-sonogenetics-as-drug-free-therapy-for-peripheral-neuropathy 2026-04-08T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-discontinues-brensocatib-development-for-hidradenitis-suppurativa-after-phase-2b-trial-fails-to-meet-endpoints 2026-04-08T01:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/hexembio-secures-10-4m-to-advance-blood-stem-cell-rejuvenation-therapy-for-cancer-treatment 2026-04-07T21:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/samchundang-pharmaceutical-completes-global-patent-restructuring-for-s-pass-oral-drug-delivery-platform 2026-04-07T21:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/bioora-and-octane-biotech-partner-to-scale-car-t-manufacturing-using-automated-cocoon-platform 2026-04-07T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-updates-metastatic-breast-cancer-guideline-molecular-subtyping-and-adcs-reshape-the-2026-treatment-landscape 2026-04-07T21:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/insufficient-source-material-available-for-medical-news-article 2026-04-07T21:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/cornell-scientists-achieve-breakthrough-in-reversible-male-contraception-using-meiosis-disruption 2026-04-07T21:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-nexus-aortic-arch-stent-graft-system-for-minimally-invasive-treatment-of-complex-aortic-disease 2026-04-07T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/merakris-therapeutics-reports-positive-interim-data-for-mtx-001-in-venous-leg-ulcers-advances-toward-late-stage-development 2026-04-07T17:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/biorestorative-therapies-partners-with-leading-dermatologist-dr-david-goldberg-to-advance-regenerative-aesthetics-platform 2026-04-07T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/inhibikase-therapeutics-initiates-phase-3-improve-pah-trial-for-novel-pulmonary-arterial-hypertension-treatment 2026-04-07T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/tempramed-secures-key-patents-for-temperature-controlled-medication-storage-devices-in-brazil-and-india 2026-04-07T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/catalym-initiates-phase-2b-trial-of-visugromab-in-second-line-hepatocellular-carcinoma-treatment 2026-04-07T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/singlomics-initiates-first-in-human-trial-of-dxp-106-novel-il-1rap-antibody-for-advanced-solid-tumors 2026-04-07T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-denoza-apotex-s-denosumab-biosimilar-for-osteoporosis-treatment 2026-04-07T17:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/alzheon-initiates-phase-1-trial-of-alz-507-next-generation-oral-alzheimer-s-drug-with-apoe4-corrector-mechanism 2026-04-07T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-and-lilly-expand-tau-targeting-collaboration-with-chf-10-million-amendment-for-alzheimer-s-disease 2026-04-07T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-approves-two-orphan-drugs-for-hiv-and-lung-cancer-patients-with-limited-treatment-options 2026-04-07T13:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/allelica-partners-with-mass-general-brigham-for-proact-3-trial-testing-polygenic-risk-score-impact-on-cardiovascular-prevention 2026-04-07T13:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/abion-s-abn202-demonstrates-superior-anti-cancer-activity-over-trop2-targeting-adcs-in-preclinical-studies 2026-04-07T09:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/renovare-therapeutics-emerges-from-stealth-mode-with-33-5m-arpa-h-funding-for-osteoarthritis-regenerative-therapies 2026-04-07T09:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-dual-target-bispecific-lunsekimig-shows-promise-in-phase-2-respiratory-disease-studies 2026-04-07T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/valitor-s-vltr-559-shows-extended-six-month-durability-in-wet-amd-preclinical-studies 2026-04-07T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharmaceutical-development-faces-translational-bottleneck-as-field-accelerates 2026-04-07T06:45:51+00:00 hourly 0.9 https://trial.medpath.com/news/invera-medical-receives-fda-clearance-for-novel-non-thermal-catheter-device-for-chronic-venous-disease-treatment 2026-04-07T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vanderbilt-center-partners-with-saravir-biopharma-to-develop-novel-monoclonal-antibody-therapy-for-measles 2026-04-07T01:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-legislature-considers-exempting-orphan-drugs-from-state-pricing-caps-amid-industry-and-consumer-advocacy-debate 2026-04-07T01:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/artemilife-s-artemisia-infused-coffee-nears-phase-2-completion-for-prostate-cancer-maintenance-therapy 2026-04-07T01:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/pol-theta-enzyme-drives-dna-repair-at-broken-replication-forks-revealing-new-cancer-vulnerability 2026-04-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/merit-medical-acquires-view-point-medical-for-140-million-to-expand-breast-cancer-localization-portfolio 2026-04-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/apple-s-studio-display-xdr-receives-fda-clearance-for-medical-imaging-applications 2026-04-06T21:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/evommune-s-evo756-misses-primary-endpoint-in-phase-2b-chronic-spontaneous-urticaria-trial-pivots-to-atopic-dermatitis-and-migraine 2026-04-06T21:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/alar-pharmaceuticals-reports-breakthrough-phase-1-results-for-long-acting-ketamine-injectable-ala-3000-in-treatment-resistant-depression 2026-04-06T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/upsher-smith-expands-generic-portfolio-with-launch-of-cyclosporine-ophthalmic-emulsion-targeting-1-9-billion-market 2026-04-06T21:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/delfi-diagnostics-presents-five-studies-on-ai-driven-cfdna-platform-for-cancer-detection-and-monitoring-at-aacr-2026 2026-04-06T17:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/tenvie-therapeutics-initiates-first-in-human-trial-of-cns-penetrant-nlrp3-inhibitor-tnv262-for-obesity-and-cardiovascular-disease 2026-04-06T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-subcutaneous-tepezza-shows-77-response-rate-in-phase-3-thyroid-eye-disease-trial 2026-04-06T17:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/iavi-initiates-first-in-human-trial-of-single-dose-marburg-virus-vaccine-candidate 2026-04-06T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/sk-life-science-to-present-comprehensive-cenobamate-data-and-patient-provider-communication-study-at-aan-2026 2026-04-06T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/isatuximab-based-quadruplet-therapy-significantly-improves-mrd-negativity-in-newly-diagnosed-multiple-myeloma 2026-04-06T17:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/united-health-products-secures-fda-approval-for-new-clinical-study-partnership-to-advance-cellustat-hemostatic-gauze 2026-04-06T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-edinburgh-researchers-identify-key-cellular-mechanism-driving-fibrosis-in-crohn-s-disease 2026-04-06T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/the-rise-of-unregulated-wellness-peptides-experts-warn-of-safety-gaps-and-unknown-long-term-risks 2026-04-06T17:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-biosignals-raises-97-million-series-b-to-advance-at-home-eeg-brain-health-platform 2026-04-06T13:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/stipple-bio-secures-100-million-series-a-to-advance-novel-adc-platform-targeting-tumor-specific-epitopes 2026-04-06T13:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-pharmaceuticals-appoints-sandeep-m-menon-as-chief-research-and-development-officer 2026-04-06T13:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/kowa-s-k-679-aduc-achieves-ultra-high-drug-loading-with-superior-tumor-distribution-in-preclinical-studies 2026-04-06T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/quizartinib-combination-therapy-shows-promise-in-phase-ii-trial-for-flt3-itd-aml 2026-04-06T13:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-acquires-soleno-therapeutics-for-2-9-billion-adding-first-in-class-pws-treatment 2026-04-06T13:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/profusa-expands-into-precision-diagnostics-with-30m-panomics-platform-acquisition-and-mayo-clinic-partnership 2026-04-06T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/humira-biosimilar-uptake-surges-after-cvs-formulary-change-then-declines-amid-nocebo-effect-concerns 2026-04-05T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/catheter-precision-presents-new-clinical-data-for-vivo-and-locket-systems-at-heart-rhythm-society-meeting 2026-04-05T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/corflow-therapeutics-advances-heart-attack-treatment-with-successful-phase-1-completion-and-phase-2-initiation-of-moca-ii-pivotal-trial 2026-04-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/indian-cancer-drug-manufacturers-seek-50-price-increase-as-platinum-costs-surge 2026-04-05T21:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/abu-dhabi-advances-neural-stem-cell-research-with-patient-derived-cell-reprogramming-technology 2026-04-05T13:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-restores-hearing-in-90-of-patients-with-genetic-deafness-in-landmark-clinical-trial 2026-04-05T05:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-real-world-study-reveals-safer-second-line-diabetes-drug-options-for-elderly-patients 2026-04-05T01:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-pharmaceuticals-secures-global-rights-to-telomir-1-through-teli-acquisition-advances-toward-triple-negative-breast-cancer-trial 2026-04-04T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-faces-pressure-to-reverse-peptide-safety-restrictions-under-kennedy-leadership 2026-04-04T01:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-announces-major-restructuring-with-247-job-cuts-in-massachusetts-to-fund-late-stage-pipeline 2026-04-03T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/cocoon-trial-prophylactic-dermatologic-protocol-halves-skin-toxicities-in-egfr-mutant-nsclc-patients-on-amivantamab-lazertinib 2026-04-03T21:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/gi-innovation-advances-cancer-immunotherapy-pipeline-with-asco-presentation-and-phase-2-trial-approval 2026-04-03T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-terminates-hiv-drug-trial-after-fda-maintains-safety-hold 2026-04-03T21:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recalls-over-3-million-eye-drop-bottles-due-to-sterility-concerns 2026-04-03T21:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-electroacupuncture-shows-promise-for-cognitive-symptoms-in-breast-cancer-survivors 2026-04-03T21:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-appoints-kim-popovits-to-board-of-directors-as-ed-mathers-departs 2026-04-03T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-rules-omitted-coinventor-renders-patents-invalid-when-correction-procedures-cannot-be-met 2026-04-03T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/texas-biomed-researchers-test-first-potential-measles-treatment-as-cases-surge-nationwide 2026-04-03T17:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-cn-105-shows-promise-in-reducing-postoperative-delirium-in-older-adults 2026-04-03T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-finds-enzyme-blend-eases-joint-pain-in-92-of-dogs-with-arthritis 2026-04-03T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/anthropic-acquires-ai-biotech-startup-coefficient-bio-for-400-million-to-advance-drug-discovery 2026-04-03T09:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/oral-drug-n-ppg-shows-complete-prevention-of-kidney-stones-and-death-in-rare-disease-model 2026-04-03T05:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-receives-fda-approval-for-generic-nintedanib-capsules-to-treat-idiopathic-pulmonary-fibrosis 2026-04-03T05:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-flu-vaccine-linked-to-55-lower-alzheimer-s-risk-in-adults-over-65 2026-04-03T05:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/iterative-health-expands-cardiovascular-research-network-through-strategic-partnership-and-acquisition 2026-04-03T05:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-partners-with-trinetx-in-200-million-deal-to-access-300-million-patient-health-records-for-drug-discovery 2026-04-03T01:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasensitive-blood-test-hpv-deepseek-predicts-recurrence-and-survival-in-hpv-associated-head-and-neck-cancer 2026-04-02T21:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/perceptive-discovery-expands-in-vitro-capabilities-with-five-fold-facility-increase-to-accelerate-oncology-drug-development 2026-04-02T21:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/st-jude-scientists-discover-how-to-restore-dendritic-cell-function-to-enhance-cancer-immunotherapy 2026-04-02T21:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/acurion-raises-4-3-million-to-advance-ai-powered-cancer-biomarker-detection-platform 2026-04-02T21:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/o-shaughnessy-ventures-backs-bioengineer-developing-gene-therapy-for-rare-muscular-dystrophy-she-lives-with 2026-04-02T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-three-existing-drugs-with-potential-for-epilepsy-treatment-through-computational-screening 2026-04-02T20:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-dual-hif-1-2-inhibitors-achieve-complete-tumor-remission-in-combination-with-immunotherapy 2026-04-02T17:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/mission-biocapital-opens-4-million-2026-platinum-program-for-global-biotech-startups 2026-04-02T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/panoramic-health-and-west-coast-kidney-institute-launch-specialized-research-institute-for-cardio-renal-metabolic-trials 2026-04-02T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/neutrolis-reports-positive-phase-1a-results-for-first-in-class-net-targeting-therapy-ntr-1011 2026-04-02T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/glycomine-completes-enrollment-in-phase-2b-polar-study-of-glm101-for-rare-genetic-disorder-pmm2-cdg 2026-04-02T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/earendil-labs-initiates-phase-iia-trial-of-half-life-extended-anti-tl1a-antibody-hxn-1001-for-ulcerative-colitis 2026-04-02T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/palleon-pharmaceuticals-to-present-first-in-class-b7-h3-targeted-sialidase-hlx316-e-688-at-aacr-2026 2026-04-02T17:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/cellcarta-and-pillar-biosciences-form-strategic-partnership-to-accelerate-ngs-tumor-profiling-for-oncology-trials 2026-04-02T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-therapeutics-partners-with-techforce-robotics-to-commercialize-ai-enhanced-gmp-manufacturing-platform 2026-04-02T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/canwell-pharma-receives-fda-clearance-for-can016-dual-payload-adc-in-her2-positive-tumors 2026-04-02T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-completes-acquisition-of-jsr-chromatography-business-to-expand-protein-a-purification-capabilities 2026-04-02T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/triple-hair-initiates-phase-iii-trial-for-th07-triple-combination-therapy-in-male-pattern-baldness 2026-04-02T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/context-therapeutics-receives-fda-fast-track-designation-for-ctim-76-in-platinum-resistant-ovarian-cancer 2026-04-02T13:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/immunovant-s-batoclimab-fails-phase-3-thyroid-eye-disease-trials-despite-early-promise 2026-04-02T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/priovant-launches-phase-2b-3-trial-for-brepocitinib-in-lichen-planopilaris-targeting-rare-scarring-hair-loss-disorder 2026-04-02T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-biontech-halt-covid-19-vaccine-trial-for-adults-50-64-due-to-enrollment-challenges 2026-04-02T13:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/merck-initiates-pivotal-phase-2b-3-trial-for-novel-bispecific-antibody-mk-8748-in-wet-age-related-macular-degeneration 2026-04-02T13:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/avencell-doses-first-patient-with-world-s-first-crispr-engineered-dual-targeting-allogeneic-car-t-therapy 2026-04-02T13:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/middle-east-disruption-impacts-6-7-of-global-clinical-trials-threatening-drug-development-pipeline 2026-04-02T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/aneuvo-secures-fda-clearance-for-exastim-spinal-cord-stimulation-system-following-22m-series-c 2026-04-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/medibeacon-s-transdermal-kidney-function-monitor-receives-european-ce-mark-certification 2026-04-02T09:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/generare-secures-eur20m-series-a-to-unlock-cryptic-molecular-chemistry-from-microbial-genomes 2026-04-02T09:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-second-glp-1-pill-for-weight-loss-with-fewer-usage-restrictions 2026-04-02T05:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/digital-twin-hearts-show-100-success-rate-in-first-clinical-trial-for-ventricular-tachycardia-ablation 2026-04-02T01:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-introduces-new-pre-order-procedure-to-address-patent-reexamination-gaming-tactics 2026-04-02T01:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/onemednet-partners-with-onco-innovations-to-accelerate-pnkp-inhibitor-development-using-ai-powered-real-world-data 2026-04-02T01:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/dulaglutide-shows-promise-for-coronary-plaque-stabilization-in-type-2-diabetes-patients 2026-04-02T01:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-ceo-opposes-congressional-codification-of-trump-s-most-favored-nation-drug-pricing-deals 2026-04-02T01:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/mirtazapine-shows-promise-for-methamphetamine-use-disorder-in-phase-3-trial 2026-04-02T01:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/aav-gene-therapy-pipeline-surpasses-250-candidates-as-fda-approvals-and-late-stage-trials-accelerate-in-2026 2026-04-02T01:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/fore-biotherapeutics-receives-first-ever-breakthrough-therapy-designation-for-high-grade-glioma-targeted-therapy 2026-04-02T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/redwood-ai-partners-with-ubc-to-develop-novel-alzheimer-s-therapeutics-targeting-nudt5-protein 2026-04-02T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/single-ketamine-infusion-rapidly-reduces-depression-and-suicidal-thoughts-within-hours-major-review-finds 2026-04-02T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/uk-universities-develop-revolutionary-stem-cell-therapy-for-hirschsprung-disease 2026-04-01T21:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/marksans-pharma-receives-fda-approval-for-generic-benzonatate-capsules-shares-surge-9 2026-04-01T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/pulmobiomed-receives-ce-mark-for-first-deep-lung-breath-sampling-device-addressing-40-year-clinical-challenge 2026-04-01T21:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/syneron-bio-secures-150m-series-b-to-advance-macrocyclic-peptide-drug-discovery-platform 2026-04-01T21:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/lord-trial-shows-active-surveillance-may-be-safe-alternative-to-surgery-for-low-risk-dcis 2026-04-01T21:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-c-diff-vaccine-trial-launches-at-university-of-washington-to-protect-high-risk-older-adults 2026-04-01T21:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/orion-corporation-appoints-berkeley-vincent-as-executive-vice-president-of-innovative-medicines 2026-04-01T17:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/geropharm-advances-biosimilar-development-with-phase-i-trials-for-novo-nordisk-s-diabetes-combination-therapy 2026-04-01T17:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-to-close-singapore-manufacturing-plant-by-february-2027-amid-revenue-decline 2026-04-01T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/anixa-biosciences-advances-breast-cancer-vaccine-to-phase-2-following-successful-phase-1-trial 2026-04-01T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-launches-next-generation-cell-line-development-platform-to-accelerate-biologics-manufacturing 2026-04-01T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/vascarta-s-topical-curcumin-gel-vas-101-shows-significant-pain-reduction-in-knee-osteoarthritis-phase-1b-trial 2026-04-01T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/tango-therapeutics-strengthens-leadership-team-with-key-executive-appointments-to-advance-precision-oncology-pipeline 2026-04-01T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/who-recommended-antibiotics-effective-in-only-25-of-neonatal-sepsis-cases-in-low-income-countries 2026-04-01T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-nicotine-pouch-approvals-amid-youth-addiction-concerns 2026-04-01T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/nih-researchers-develop-novel-opioid-dfnz-with-potent-pain-relief-and-reduced-addiction-risk 2026-04-01T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-benralizumab-achieves-50-reduction-in-hes-flares-in-phase-3-trial 2026-04-01T17:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-develop-smart-dna-drug-system-that-targets-cancer-cells-with-computer-like-precision 2026-04-01T13:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/symeres-and-ambagon-partner-to-develop-molecular-glue-therapeutics-for-colorectal-cancer 2026-04-01T13:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/bd-expands-ai-powered-medication-dispensing-system-to-european-market 2026-04-01T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/fosun-pharma-receives-nmpa-approval-for-phase-1-trial-of-hlx319-biosimilar-for-breast-cancer-treatment 2026-04-01T13:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-pioneering-partners-with-aws-to-accelerate-ai-driven-drug-discovery-across-portfolio-companies 2026-04-01T13:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/prism-als-initiative-launches-to-address-critical-gap-in-als-drug-discovery-through-patient-derived-stem-cell-models 2026-04-01T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-completes-enrollment-in-phase-2-gene-therapy-trial-for-heart-failure 2026-04-01T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/nj-bio-and-ajinomoto-bio-pharma-services-partner-to-advance-antibody-drug-conjugate-development-through-ajicaptm-platform-integration 2026-04-01T01:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/inhibitor-therapeutics-advances-itraconazole-program-for-gorlin-syndrome-with-novel-amorphous-formulation 2026-04-01T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-section-3-d-and-compulsory-licensing-how-indian-patent-law-balances-innovation-and-affordable-access-to-life-saving-medicines 2026-04-01T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-niacin-shows-promise-in-glioblastoma-early-trial-reports-28-improvement-in-disease-progression 2026-04-01T01:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/iontronic-click-to-release-electrically-controlled-drug-delivery-enters-a-new-era 2026-04-01T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/kenya-launches-lenacapavir-hiv-prevention-program-but-access-barriers-persist-in-high-risk-communities 2026-04-01T01:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/xbrane-resubmits-ranibizumab-biosimilar-application-to-fda-following-manufacturing-site-corrections 2026-04-01T01:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/lg-chem-acquires-worldwide-rights-to-first-in-class-p53-y220c-cancer-drug-fmc-220 2026-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pelthos-therapeutics-initiates-phase-1b-2a-trial-of-ct2000-eye-drops-for-chronic-ocular-pain-in-dry-eye-disease 2026-03-31T21:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/cancervax-achieves-breakthrough-in-targeted-lipid-nanoparticle-delivery-avoiding-liver-toxicity-in-mouse-studies 2026-03-31T21:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-approval-for-cerebral-venous-stent-to-treat-severe-idiopathic-intracranial-hypertension 2026-03-31T21:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/affinity-purification-combined-with-vazyme-elisa-sets-new-benchmark-for-dsrna-control-in-mrna-manufacturing 2026-03-31T21:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/amylin-drug-development-surges-with-19-billion-investment-as-nearly-40-programs-target-obesity-treatment 2026-03-31T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/adcytherix-doses-first-patient-in-phase-1-trial-of-adcx-020-marking-transition-to-clinical-stage-company 2026-03-31T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/tippingpoint-biosciences-secures-4-5m-to-target-undruggable-epigenetic-interfaces-in-pediatric-brain-cancer 2026-03-31T17:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/pheast-therapeutics-advances-phst001-anti-cd24-antibody-into-phase-1b-combination-trials 2026-03-31T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/hemogenyx-pharmaceuticals-completes-manufacturing-tech-transfer-for-hg-ct-1-car-t-therapy-expands-clinical-trial-to-pediatric-aml-patients 2026-03-31T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/ambros-therapeutics-secures-key-patent-for-precision-medicine-approach-to-treating-complex-regional-pain-syndrome 2026-03-31T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-s-env-294-shows-85-easi-reduction-in-phase-1b-atopic-dermatitis-trial 2026-03-31T17:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-secures-100-million-in-financing-to-support-global-expansion-of-anktiva-immunotherapy 2026-03-31T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/tarsus-pharmaceuticals-initiates-phase-2-trial-for-first-oral-lyme-disease-prevention-therapy 2026-03-31T17:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-marketing-crackdown-to-cancer-biologics-targets-four-major-companies-over-misleading-survival-claims 2026-03-31T17:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/proxygen-appoints-chiara-conti-as-cso-to-accelerate-molecular-glue-platform-into-clinical-development 2026-03-31T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/infinimmune-partners-with-merck-in-838-million-antibody-discovery-deal 2026-03-31T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/cellcentric-launches-pivotal-phase-2-trial-of-inobrodib-combination-for-relapsed-multiple-myeloma 2026-03-31T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/final-arrow-study-data-shows-pralsetinib-achieves-70-response-rate-in-ret-nsclc-with-durable-survival-outcomes 2026-03-31T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/restore-robotics-expands-fda-cleared-robotic-instrument-portfolio-with-two-additional-da-vinci-xi-clearances 2026-03-31T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/gan-lee-s-once-weekly-insulin-gzr4-demonstrates-superior-efficacy-in-phase-3-trials 2026-03-31T17:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/i-lumen-scientific-receives-fda-ide-approval-to-expand-bioelectric-stimulation-trial-for-dry-amd-to-u-s 2026-03-31T17:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-launches-primary-evaluation-system-for-independent-drug-approval 2026-03-31T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/altamira-therapeutics-expands-nucleic-acid-delivery-platform-with-dna-technology-and-advances-spin-off-plans 2026-03-31T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-acquires-centessa-pharmaceuticals-for-up-to-7-8-billion-to-expand-sleep-disorder-portfolio 2026-03-31T13:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/semarion-secures-3-8m-to-scale-cell-based-drug-discovery-platform 2026-03-31T13:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-acquires-apellis-for-5-6-billion-expanding-immunology-and-rare-disease-portfolio 2026-03-31T13:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-efzimfotase-alfa-shows-promise-in-phase-iii-hypophosphatasia-trials-with-mixed-results 2026-03-31T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/sirpad-trial-demonstrates-superior-efficacy-of-sirolimus-coated-balloons-in-peripheral-artery-disease-treatment 2026-03-31T13:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-signablok-s-trem-1-inhibitor-for-retinopathy-of-prematurity 2026-03-31T13:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-fasenra-for-hypereosinophilic-syndrome-based-on-phase-iii-natron-trial-results 2026-03-31T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/signadori-bio-appoints-dr-selwyn-ho-as-ceo-to-advance-novel-monocyte-immunotherapy-platform 2026-03-31T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-partners-with-hackensack-meridian-health-to-advance-novel-ansamycin-antibiotics-for-non-tuberculous-mycobacteria 2026-03-31T09:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/4basebio-expands-manufacturing-capacity-with-new-26500-square-foot-cambridge-facility-to-meet-growing-synthetic-dna-demand 2026-03-31T09:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-advances-polb-001-cancer-therapy-with-fda-approval-and-canadian-patent 2026-03-31T09:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/toppan-holdings-launches-us-subsidiary-to-advance-personalized-cancer-medicine-using-3d-cell-culture-technology 2026-03-31T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/crown-reserve-acquisition-corp-i-and-carvix-announce-1-0-billion-business-combination-agreement 2026-03-31T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-reports-promising-first-in-human-data-for-personalized-mrna-cancer-vaccine-evm16 2026-03-31T05:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/fluvoxamine-shows-promise-for-long-covid-fatigue-in-international-clinical-trial 2026-03-31T01:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-gene-therapy-candidate-mma-101-to-treat-rare-metabolic-disorder-methylmalonic-acidemia 2026-03-31T01:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-acquires-soleno-therapeutics-for-2-9-billion-in-rare-disease-expansion 2026-03-31T01:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/haemonetics-receives-fda-approval-for-expanded-vascade-mvp-xl-labeling-to-support-advanced-atrial-fibrillation-procedures 2026-03-31T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/4dmedical-secures-ce-mark-for-revolutionary-ct-vqtm-lung-imaging-technology-opens-european-market 2026-03-31T01:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-quality-leader-advocates-for-supply-chain-wide-quality-culture-beyond-compliance 2026-03-31T00:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/neural-progenitor-cell-transplants-show-promise-for-spinal-cord-repair-through-motor-circuit-reconnection 2026-03-30T21:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/butterfly-network-receives-first-fda-clearance-for-ai-powered-gestational-age-ultrasound-tool 2026-03-30T21:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/triglyceride-lowering-drug-olezarsen-fails-to-reduce-arterial-plaque-despite-60-triglyceride-reduction 2026-03-30T21:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-oral-cholesterol-drug-enlicitide-shows-64-6-ldl-reduction-in-late-stage-trial 2026-03-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/smart-decision-trial-shows-beta-blocker-discontinuation-safe-for-low-risk-post-mi-patients 2026-03-30T21:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/ap-biosciences-and-tasly-amend-collaboration-to-accelerate-global-development-of-dual-target-cancer-therapy-ap505 2026-03-30T21:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/cynata-therapeutics-completes-phase-2-trial-evaluation-for-stem-cell-therapy-targeting-acute-graft-versus-host-disease 2026-03-30T21:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/blackstone-closes-record-6-3-billion-life-sciences-fund-largest-private-investment-vehicle-in-sector-history 2026-03-30T21:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-arizona-launches-12-million-phase-3-trial-testing-rapamycin-for-healthy-aging 2026-03-30T21:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-secures-major-commercial-agreement-with-top-5-pharma-company-for-ai-driven-depression-drug-discovery 2026-03-30T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharma-and-braveheart-bio-report-promising-phase-2-results-for-next-generation-cardiac-myosin-inhibitor-in-obstructive-hypertrophic-cardiomyopathy 2026-03-30T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-spravato-shows-sustained-antidepressant-effects-six-months-after-treatment-discontinuation-in-real-world-study 2026-03-30T17:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/tartan-hf-trial-reveals-one-in-four-diabetics-has-undiagnosed-heart-failure 2026-03-30T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ultragenyx-ind-application-for-ux016-to-treat-rare-gne-myopathy 2026-03-30T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/calliditas-therapeutics-presents-new-nefigard-trial-data-supporting-nefecon-s-gut-targeted-mechanism-in-iga-nephropathy 2026-03-30T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/emboline-s-emboliner-system-achieves-superior-debris-capture-in-pivotal-tavr-protection-trial 2026-03-30T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/vor-bio-initiates-global-phase-3-trial-of-telitacicept-for-primary-sjogren-s-disease 2026-03-30T13:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-and-abbvie-sue-washington-state-over-new-340b-drug-pricing-transparency-law 2026-03-30T13:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/prilenia-and-ferrer-launch-pivotal-phase-3-trial-of-pridopidine-for-rapidly-progressive-als 2026-03-30T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/dompe-initiates-phase-2-trial-of-intranasal-ngf-for-spastic-cerebral-palsy-in-italy 2026-03-30T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-receives-fda-clearance-for-asurys-fluid-management-system-to-address-kidney-stone-treatment-challenges 2026-03-30T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/harmonicare-receives-fda-approval-for-fgfr2-3-inhibitor-absk061-clinical-trial-in-pediatric-achondroplasia 2026-03-30T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/nanobiotix-reports-promising-early-data-from-phase-2-lung-cancer-trial-of-jnj-1900-radioenhancer 2026-03-30T09:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-cobas-mpx-e-assay-revolutionary-4-in-1-blood-screening-test-enhances-global-blood-supply-safety 2026-03-30T09:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/algorae-pharmaceuticals-advances-ai-driven-drug-discovery-with-second-peter-maccallum-cancer-centre-collaboration 2026-03-30T09:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/noninvasive-lung-impedance-monitoring-cuts-heart-failure-hospitalizations-by-74-in-hfpef-patients 2026-03-30T05:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/nih-commits-720k-to-co-fund-phase-ii-mesenchymal-stem-cell-trial-for-moderate-to-severe-lupus 2026-03-30T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-microneedle-patch-enables-non-invasive-immune-system-monitoring 2026-03-30T01:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/first-placebo-controlled-trial-shows-angioplasty-significantly-reduces-angina-in-chronic-total-occlusion-patients 2026-03-30T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-lnp-therapy-with-mtor-inhibition-reprograms-allergic-responses-in-preclinical-model 2026-03-29T21:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/spirit-hf-trial-shows-no-benefit-and-safety-concerns-for-spironolactone-in-heart-failure-with-preserved-ejection-fraction 2026-03-29T21:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-safety-of-biologic-therapies-in-asthma-shows-reduced-pneumonia-risk 2026-03-29T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-s-cobenfy-shows-stable-transition-profile-in-phase-4-schizophrenia-trial 2026-03-29T17:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/yingen-bio-s-her2-adc-db-1303-receives-marketing-approval-acceptance-in-china-for-breast-cancer-treatment 2026-03-29T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/key-phase-3-trials-from-moderna-sarepta-and-krystal-biotech-set-to-drive-2026-biotech-performance 2026-03-29T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/fast-iii-trial-shows-non-invasive-vffr-technology-matches-gold-standard-ffr-for-coronary-revascularization-guidance 2026-03-29T17:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-abandons-pbs-negotiations-for-mounjaro-leaving-450000-australians-without-subsidized-access 2026-03-29T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/grand-pharmaceutical-secures-china-approval-for-eye-treatment-gpn01768-advances-migraine-drug-to-phase-ii 2026-03-29T13:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-secures-nmpa-approval-for-phase-i-iia-trial-of-bispecific-adc-rc288-in-solid-tumors 2026-03-29T05:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/tonlamarsen-shows-promise-in-resistant-hypertension-despite-mixed-phase-2-results 2026-03-29T01:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/repatha-reduces-first-major-cardiovascular-events-by-31-in-high-risk-patients-without-significant-atherosclerosis 2026-03-29T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/tens-therapy-shows-sustained-pain-relief-for-fibromyalgia-patients-in-large-real-world-trial 2026-03-28T21:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/anumana-receives-fda-clearance-for-first-ecg-ai-algorithm-to-detect-early-pulmonary-hypertension 2026-03-28T21:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-s-povorcitinib-shows-71-response-rate-in-late-stage-hidradenitis-suppurativa-trials 2026-03-28T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-ekos-system-shows-superior-outcomes-in-pulmonary-embolism-treatment 2026-03-28T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bayer-s-lynkuet-as-first-nonhormonal-menopause-treatment-for-hot-flashes 2026-03-28T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/impella-cp-heart-pump-fails-to-reduce-infarct-size-in-major-stemi-trial 2026-03-28T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/champion-af-trial-shows-watchman-flx-device-non-inferior-to-blood-thinners-for-stroke-prevention-in-atrial-fibrillation 2026-03-28T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-seeks-court-led-dissolution-following-failed-fundraising-and-orlynvah-sales-struggles 2026-03-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/portable-tacs-shows-promise-for-treatment-resistant-depression-in-multicenter-randomized-trial 2026-03-28T10:41:24+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-manchester-receives-ps1-million-to-develop-snail-inspired-soft-robots-for-bowel-cancer-drug-delivery 2026-03-28T05:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-appoints-shreehas-tambe-as-ceo-following-major-organizational-restructuring 2026-03-28T05:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/bamf-health-advances-theranostic-treatment-for-colorectal-cancer-in-west-michigan-clinical-trials 2026-03-28T01:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/pig-semen-derived-eye-drops-show-promise-for-retinoblastoma-treatment-in-preclinical-studies 2026-03-28T01:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-fibromun-and-nidlegy-face-mixed-clinical-trial-results-in-cancer-studies 2026-03-28T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-wireless-implantable-device-to-solve-oxygen-challenge-in-cell-based-drug-delivery 2026-03-28T01:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-ct-screening-reduces-lung-cancer-mortality-by-55-in-non-risk-based-population 2026-03-27T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/ysios-capital-launches-eur100m-inceptionbio-fund-to-catalyze-spanish-biotech-spinouts 2026-03-27T21:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/nkarta-secures-fda-approval-for-outpatient-car-nk-cell-therapy-administration-in-autoimmune-disease-trials 2026-03-27T17:12:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-phase-1-pediatric-cns-cancer-trial-for-star-001-combination-therapy 2026-03-27T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-team-develops-implantable-living-pharmacy-device-that-produces-multiple-drugs-simultaneously 2026-03-27T17:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-amgen-s-tarlatamab-for-relapsed-small-cell-lung-cancer 2026-03-27T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-acquires-transcend-therapeutics-for-1-2-billion-to-advance-ptsd-treatment-with-breakthrough-therapy-tsnd-201 2026-03-27T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/arletta-pharma-s-lybridotm-shows-statistically-significant-improvement-in-female-sexual-dysfunction-phase-ii-trial 2026-03-27T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/prf-technologies-advances-ocuring-k-intraocular-ring-for-cataract-surgery-through-phase-i-safety-studies 2026-03-27T13:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-acquires-excellergy-for-up-to-2-billion-to-strengthen-immunology-portfolio 2026-03-27T13:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-tozorakimab-achieves-primary-endpoints-in-phase-iii-copd-trials-demonstrating-significant-reduction-in-exacerbations 2026-03-27T13:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/lifecore-biomedical-secures-two-new-cdmo-agreements-including-fourth-commercial-site-transfer-in-five-months 2026-03-27T09:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/espresso-trial-challenges-more-therapy-earlier-paradigm-in-stroke-rehabilitation 2026-03-27T09:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/intelligent-bio-solutions-secures-eighth-european-patent-for-advanced-fingerprint-drug-testing-technology 2026-03-27T05:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/pinnacle-medicines-raises-89-million-series-b-to-advance-oral-peptide-therapeutics-into-clinical-trials 2026-03-27T05:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/lunai-bioworks-acquires-blood-brain-barrier-delivery-platform-in-20m-deal-to-advance-alzheimer-s-therapeutics 2026-03-27T01:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/allogene-therapeutics-reports-promising-data-for-off-the-shelf-car-t-therapy-in-b-cell-lymphoma 2026-03-27T01:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/vivani-medical-advances-npm-139-semaglutide-implant-toward-phase-1-trial-following-successful-preclinical-data 2026-03-27T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novo-nordisk-s-awiqli-first-once-weekly-basal-insulin-for-type-2-diabetes 2026-03-27T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-s-anti-diabetic-effects-linked-to-brain-mechanism-involving-rap1-protein 2026-03-27T01:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/rubedo-life-sciences-reports-positive-phase-1-results-for-first-in-class-gpx4-modulator-rls-1496-in-dermatological-conditions 2026-03-27T01:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-appoints-rick-mcelheny-as-senior-vp-of-business-development-to-accelerate-bioengineered-tissue-partnerships 2026-03-26T21:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-cd7-car-t-cell-therapy-shows-93-5-response-rate-in-relapsed-t-cell-lymphomas 2026-03-26T21:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/herbalife-acquires-personalized-supplement-startup-bioniq-for-up-to-150m-to-scale-data-driven-nutrition 2026-03-26T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/pulmatrix-and-eos-senolytix-announce-19-million-merger-to-advance-anti-aging-mitochondrial-therapies 2026-03-26T21:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/oig-approves-medicare-cost-sharing-subsidies-for-heart-failure-device-clinical-trial 2026-03-26T17:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/eurofins-viracor-launches-rapid-car-t-cell-monitoring-assay-for-obe-cel-therapy 2026-03-26T17:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-appoints-principal-investigator-for-phase-2-multiple-sclerosis-trial-of-lucid-ms 2026-03-26T17:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/made-scientific-partners-with-njit-to-launch-graduate-cell-and-gene-therapy-bioprocessing-program 2026-03-26T17:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-zenkuda-achieves-primary-endpoint-in-phase-3-diabetic-retinopathy-trial 2026-03-26T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharm-reports-strong-2025-results-with-26-2-growth-in-innovative-drug-sales 2026-03-26T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-secures-fda-approval-for-san-antonio-plasma-collection-center-expanding-specialty-plasma-production-capacity 2026-03-26T17:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-zenkuda-achieves-62-5-response-rate-in-phase-3-glow2-diabetic-retinopathy-trial 2026-03-26T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-receives-fda-breakthrough-therapy-designation-for-gene-therapy-treating-radiation-induced-dry-mouth 2026-03-26T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/mytomorrows-partners-with-spanish-academic-hospital-to-deploy-ai-powered-clinical-trial-matching-system 2026-03-26T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/edesa-biotech-prepares-phase-2-vitiligo-trial-for-mid-2026-launch-following-promising-ards-results 2026-03-26T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/neion-bio-secures-23m-series-a-to-scale-egg-based-biologics-manufacturing-platform 2026-03-26T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioptimus-launches-stela-world-s-largest-spatial-biology-atlas-to-power-ai-driven-precision-medicine 2026-03-26T13:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/invivoscribe-achieves-ivdr-class-c-certification-for-b-cell-lymphoma-diagnostic-assay-in-europe 2026-03-26T13:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/vagus-nerve-stimulation-shows-promise-for-ptsd-treatment-in-clinical-trials 2026-03-26T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-initiates-phase-1-study-of-tnx-1900-intranasal-oxytocin-for-migraine-treatment 2026-03-26T13:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/norgine-receives-swiss-approval-for-pedmarqsi-first-treatment-to-prevent-cisplatin-induced-hearing-loss-in-children 2026-03-26T13:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/innate-pharma-advances-oncology-pipeline-with-phase-3-trial-plans-and-promising-adc-data 2026-03-26T09:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/imperative-care-launches-clear-it-study-to-establish-clinical-standards-for-peripheral-thromboembolism-treatment 2026-03-26T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-and-novartis-mount-legal-challenge-against-illinois-340b-drug-discount-law 2026-03-26T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-launches-cenobamate-in-china-marking-major-milestone-for-epilepsy-treatment 2026-03-26T09:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/hmh-holding-completes-210-4-million-ipo-pricing-for-drilling-equipment-technology 2026-03-26T05:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-partners-with-converge-bio-to-accelerate-ai-driven-tri-specific-antibody-development 2026-03-26T05:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/brightgene-s-oral-glp-1-gip-dual-agonist-bgm0504-shows-promising-weight-loss-results-in-phase-1-trials 2026-03-26T05:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/elmed-life-sciences-secures-2-7m-series-a-to-expand-microbiome-based-healthcare-solutions 2026-03-26T05:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/helioliver-blood-test-shows-superior-sensitivity-over-ultrasound-for-early-hepatocellular-carcinoma-detection-in-landmark-climb-study 2026-03-26T03:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/hrt-patches-show-equal-efficacy-to-injections-for-locally-advanced-prostate-cancer-treatment 2026-03-26T01:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/flumatinib-therapeutic-drug-monitoring-reveals-key-exposure-thresholds-for-molecular-response-in-chinese-cml-cp-patients 2026-03-26T01:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/nugen-medical-devices-advances-needle-free-drug-delivery-with-dual-patent-filings-for-enhanced-injection-technology 2026-03-26T01:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/methylphenidate-may-reduce-psychosis-risk-in-children-with-adhd-large-finnish-study-shows 2026-03-26T01:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-oral-drug-delivery-technology-enables-depression-treatment-through-fat-absorption-pathways 2026-03-25T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/blood-pressure-drug-telmisartan-shows-promise-in-enhancing-cancer-treatment-effectiveness 2026-03-25T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/fish-oil-supplements-show-no-cognitive-benefit-in-alzheimer-s-prevention-usc-study-finds 2026-03-25T21:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/beyondspring-s-plinabulin-shows-promise-in-overcoming-immunotherapy-resistance-in-nsclc 2026-03-25T17:19:55+00:00 hourly 0.9 https://trial.medpath.com/news/clarity-pharmaceuticals-secures-large-scale-copper-64-manufacturing-agreement-with-theragenics-for-prostate-cancer-diagnostic 2026-03-25T17:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/tropic-biosciences-raises-105-million-series-c-to-scale-gene-edited-tropical-crop-production 2026-03-25T17:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/scitech-s-st-001-nanofenretinide-shows-early-clinical-benefit-in-cutaneous-t-cell-lymphoma-phase-1a-trial 2026-03-25T17:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/axplora-invests-60-million-in-hpapi-manufacturing-expansion-to-meet-growing-adc-demand 2026-03-25T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-apotex-s-clobivis-for-post-cataract-surgery-inflammation-treatment 2026-03-25T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/sirolimus-eluting-balloons-show-promise-as-alternative-to-permanent-stents-in-heart-attack-treatment 2026-03-25T17:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/lineage-cell-therapeutics-launches-cor1-cell-therapy-program-to-address-global-corneal-transplant-shortage 2026-03-25T13:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-court-clears-path-for-sawai-s-amitiza-generic-rejecting-viatris-patent-extension-strategy 2026-03-25T13:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/cvc-capital-proposes-eur10-9-billion-takeover-of-italian-pharma-recordati 2026-03-25T13:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/verigraft-initiates-pivotal-phase-ii-iii-trial-for-first-potential-curative-cvi-treatment 2026-03-25T13:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-receives-fda-approval-for-expanded-omniasecure-defibrillation-lead-indication 2026-03-25T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/mitsui-chemicals-establishes-drug-discovery-lab-in-kentucky-advancing-next-generation-pharmaceutical-materials 2026-03-25T09:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/veeva-systems-acquires-ai-powered-brand-engagement-platform-ostro-for-100-million 2026-03-25T09:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/hope-medicine-initiates-phase-iii-trial-for-first-in-class-non-hormonal-endometriosis-treatment 2026-03-25T05:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/absci-s-ai-designed-hair-loss-treatment-abs-201-shows-promising-safety-data-in-phase-1-2a-trial 2026-03-25T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/new-cerebrospinal-fluid-biomarker-achieves-94-97-accuracy-in-diagnosing-parkinson-s-disease-and-lewy-body-dementia 2026-03-25T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/biolojic-design-s-ai-designed-multibody-tev-325-achieves-preclinical-milestone-for-autoimmune-disease-treatment 2026-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/20-20-biolabs-partners-with-rokit-healthcare-to-integrate-ckd-prediction-technology-into-longevity-testing-platform 2026-03-24T21:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-develop-breakthrough-nanoparticle-system-for-scalable-exosome-therapeutic-production 2026-03-24T21:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-advances-phase-3-diabetic-foot-infection-trial-following-clean-indonesian-regulatory-inspection 2026-03-24T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-pharmaceuticals-settles-firdapse-patent-litigation-with-hetero-labs-securing-market-exclusivity-until-2035 2026-03-24T21:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-advances-dll3-targeting-t-cell-engager-obrixtamig-directly-to-phase-3-first-line-small-cell-lung-cancer-trial 2026-03-24T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/myosin-therapeutics-receives-2-million-florida-grant-for-first-in-human-glioblastoma-trial 2026-03-24T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-s-disitamab-vedotin-receives-fourth-nmpa-approval-for-her2-low-breast-cancer-in-china 2026-03-24T21:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-partners-with-san-raffaele-institute-to-advance-hematopoietic-stem-cell-gene-therapies 2026-03-24T21:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/italian-drug-approval-reform-shows-mixed-results-on-negotiation-timelines 2026-03-24T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-immunitybio-over-misleading-cancer-drug-claims-by-patrick-soon-shiong 2026-03-24T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/28bio-s-cns-3d-brain-organoids-demonstrate-superior-seizure-prediction-accuracy-over-animal-models 2026-03-24T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-partners-with-adare-pharma-for-cytisinicline-manufacturing-ahead-of-fda-decision 2026-03-24T17:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/doctronic-secures-40m-series-b-as-first-ai-system-legally-authorized-to-renew-prescriptions-in-the-u-s 2026-03-24T17:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/apnimed-secures-150m-from-shionogi-joint-venture-sale-advances-first-in-class-osa-drug-toward-fda-submission 2026-03-24T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/major-study-finds-no-link-between-covid-19-vaccines-and-sudden-cardiac-death-in-healthy-young-adults 2026-03-24T17:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-world-s-first-clinical-trial-integrating-ayurveda-with-tuberculosis-treatment 2026-03-24T17:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-cancer-drug-doxorubicin-shows-promise-against-drug-resistant-herpes-infections 2026-03-24T17:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-keytruda-as-first-perioperative-immunotherapy-for-head-and-neck-cancer-in-20-years 2026-03-24T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/scotland-launches-first-uk-newborn-screening-program-for-spinal-muscular-atrophy 2026-03-24T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/epifrontier-therapeutics-secures-32m-amed-grant-to-advance-first-in-class-g9a-inhibitor-for-beta-globin-disorders 2026-03-24T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/ra-capital-raises-75m-through-third-spac-targeting-china-based-biotech-companies 2026-03-24T17:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-secures-new-us-patent-for-intratumoral-cancer-technology 2026-03-24T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-partners-with-breakthrough-t1d-to-advance-novel-cell-therapy-platform-for-type-1-diabetes 2026-03-24T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-expands-pain-portfolio-with-fda-cleared-viaverte-basivertebral-nerve-ablation-system 2026-03-24T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/mushrooms-inc-achieves-proof-of-concept-for-mycelium-based-infection-detection-technology 2026-03-24T13:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/callio-therapeutics-initiates-first-in-human-trial-of-dual-payload-adc-clio-8221-for-her2-positive-solid-tumors 2026-03-24T13:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/dualitybio-achieves-phase-3-success-with-lead-adc-candidate-advances-global-pipeline-across-multiple-cancer-types 2026-03-24T13:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/mana-bio-strengthens-leadership-team-and-prepares-to-present-ai-driven-lnp-data-at-asgct-2026 2026-03-24T13:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/immutrin-secures-87-million-series-a-to-advance-novel-antibody-therapy-for-attr-amyloidosis 2026-03-24T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-bio-receives-japan-pmda-approval-for-phase-iii-car-t-trial-in-earlier-line-multiple-myeloma 2026-03-24T13:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/prestige-biopharma-s-hd204-biosimilar-meets-primary-endpoint-in-phase-3-nsclc-trial 2026-03-24T13:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-therapeutics-partners-with-merck-in-2-2-billion-ibd-drug-discovery-deal-using-somatic-genomics-platform 2026-03-24T13:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/cortexa-achieves-major-commercial-milestone-with-mdma-supply-in-australia-s-regulated-psychedelic-market 2026-03-24T09:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-challenges-takeda-s-ibd-drug-patents-in-uk-biosimilar-dispute 2026-03-24T09:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-achieves-breakthrough-in-first-line-nsclc-treatment-with-world-s-first-successful-adc-immunotherapy-combination 2026-03-24T09:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/microbot-medical-launches-full-commercial-release-of-liberty-robotic-system-following-successful-limited-market-adoption 2026-03-24T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pancreatic-cancer-pipeline-reaches-new-milestone-with-200-therapies-from-170-companies-advancing-novel-treatment-approaches 2026-03-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/sol-gel-secures-patent-extension-for-patidegib-until-2044-raises-33-1m-to-advance-gorlin-syndrome-trial 2026-03-24T01:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/surrozen-advances-wnt-based-retinal-therapeutics-pipeline-plans-ind-filing-for-szn-8141-in-second-half-of-2026 2026-03-24T01:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-s-microbiome-therapy-shows-62-response-rate-in-severe-graft-versus-host-disease 2026-03-24T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/avalyn-initiates-phase-2-trial-of-inhaled-nintedanib-for-idiopathic-pulmonary-fibrosis 2026-03-24T01:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/celosia-therapeutics-initiates-first-in-human-trial-of-ctx1000-gene-therapy-for-als 2026-03-24T01:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/cencora-expands-retina-care-network-with-1-1-billion-eyesouth-partners-acquisition 2026-03-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-s-enhanced-epicapture-test-achieves-85-accuracy-in-prostate-cancer-risk-prediction 2026-03-23T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-approves-pharmamar-s-zepzelca-combination-as-first-line-maintenance-therapy-for-advanced-small-cell-lung-cancer 2026-03-23T21:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/abpi-proposes-nhs-data-integration-to-revitalize-uk-s-declining-clinical-trial-sector 2026-03-23T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-s-unbuzzd-supplement-shows-significant-alcohol-metabolism-acceleration-in-peer-reviewed-clinical-trial 2026-03-23T17:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-s-elios-system-achieves-primary-endpoints-in-24-month-u-s-glaucoma-trial 2026-03-23T17:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/sintx-technologies-achieves-first-human-implant-of-fda-cleared-silicon-nitride-foot-and-ankle-device 2026-03-23T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/kraig-biocraft-laboratories-scales-spider-silk-production-with-new-facility-and-enhanced-r-d-capacity 2026-03-23T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/roche-opens-institute-of-human-biology-in-basel-with-chf-1-4-billion-investment-to-revolutionize-drug-discovery 2026-03-23T17:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-secures-first-ever-gad-treatment-approval-in-japan-with-effexor 2026-03-23T17:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/german-court-grants-sales-ban-for-generic-fampridine-products-following-patent-victory-for-merz 2026-03-23T17:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/bio-thera-solutions-expands-partnership-with-intas-for-golimumab-biosimilar-bat2506-in-india 2026-03-23T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-zilganersen-for-alexander-disease-setting-stage-for-first-treatment 2026-03-23T17:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/godavari-biorefineries-secures-japanese-patent-for-novel-v-atpase-inhibitor-antiviral-compounds 2026-03-23T17:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-acquires-37-stake-in-syntegon-as-pharmaceutical-packaging-giant-eyes-north-american-expansion 2026-03-23T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-secures-mrc-grant-to-advance-sbt-589-for-leigh-syndrome-treatment 2026-03-23T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-completes-2-5-billion-acquisition-of-radicava-for-als-treatment-expanding-rare-disease-portfolio 2026-03-23T17:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/enlivex-receives-fda-ind-clearance-for-phase-2b-trial-of-allocetra-in-age-related-knee-osteoarthritis 2026-03-23T17:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-s-inm-901-shows-promise-in-human-brain-organoid-models-for-alzheimer-s-disease-treatment 2026-03-23T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/glyconex-partners-with-nippon-kayaku-to-develop-tumor-activated-adc-gnx201-for-solid-tumors 2026-03-23T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/ondine-s-steriwave-phase-3-trial-reaches-93-enrollment-milestone-in-landmark-surgical-site-infection-prevention-study 2026-03-23T17:06:18+00:00 hourly 0.9